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ABSTRACT 
Multimorbidity, the presence of two or more chronic diseases in one person, is common in older people, 
and associates with a number of negative outcomes. In this thesis, we propose a methodology to assess 
and measure multimorbidity in older individuals. We use it to describe the longitudinal evolution and 
prognosis of multimorbidity clusters, and to investigate the extent to which clusters of cardiovascular 
and neuropsychiatric multimorbidity impact and interact with physical function. Data are from the 
Swedish National Study on Aging and Care in Kungsholmen (SNAC-K), a population-based study 
including 3,363 community-dwelling and institutionalized individuals aged ≥60 years. 
Study I. We provided a clinically driven list of 60 chronic diseases for the assessment of multimorbidity 
in older adults. After applying this methodology to the 3,363 SNAC-K participants, we found that 88.6% 
of them had two or more diseases, 73.2% had three or more diseases, and only 11.4% had zero or one 
single disease. Given the ceiling effect associated with the use of a cutoff, multimorbidity should be 
rather be considered as a continuous metric, which better reflects the progressive accumulation of 
diseases starting in early aging and continuing up to very late life. 
Study II. We identified and traced the evolution of multimorbidity clusters over 12 years of 2,931 
SNAC-K participants with two or more diseases. At baseline, 51.3% of participants were included in 
one of five clusters; the rest were part of an unspecified group, given that no disease patterns could 
cluster them. Cardiometabolic risk factors, the evolution of several diseases, and death may have steered 
most of the longitudinal transitions among the multimorbidity clusters we described over a period of 12 
years.  
Study III. We investigated the association of cardiovascular and neuropsychiatric multimorbidity with 
9 years of change in walking speed and intact basic activities of daily living in 2,385 SNAC-K 
participants. Neuropsychiatric disease, alone or combined with cardiovascular disease, showed the 
strongest detrimental impact on functional decline. Cardiovascular multimorbidity showed an 
association solely with decline in walking speed.  
Study IV. We studied the interplay between cardiovascular multimorbidity and functional impairment, 
as well as between neuropsychiatric multimorbidity and functional impairment, on all-cause and cause-
specific mortality in 3,241 SNAC-K participants. Slow walking speed provided additional prognostic 
information in terms of all-cause and cause-specific mortality beyond the number of both cardiovascular 
and/or neuropsychiatric diseases.  
Conclusions. The use of a standardized methodology to assess chronic disease and multimorbidity may 
enhance comparability across studies, settings, and geographical regions. Studying the natural evolution 
of multimorbidity in older individuals may help to better hypothesize about underlying mechanisms and 
provide important prognostic information. In this regard, multimorbidity clusters including 
cardiovascular and neuropsychiatric disease emerge as major determinants of functional decline and 
higher mortality rate. Finally, the adoption of a simple and easy-to-use measure of functional 
impairment such as walking speed may help health-care professionals identify older people affected by 
specific groups of chronic disease with similar needs, health trajectories, and prognoses.       
Key words. Multimorbidity; multimorbidity clusters; chronic disease; walking speed; disability; older 
people; mortality; personalized medicine.  
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SAMMANFATNING 
Multisjuklighet, närvaron av minst två kroniska sjukdomar hos en individ, är vanligt bland äldre och 
associerat med flera negativa hälsorelaterade utfall. I den här doktorsavhandlingen föreslår vi ett sätt att 
mäta och bedöma multisjuklighet hos äldre individer, metoden används för att förklara den 
longitudinella utvecklingen och prognosen för olika kluster av multisjuklighet. Vi undersöker till vilken 
grad olika kluster av kardiovaskulära och neuropsykiatriska sjukdomar påverkar och interagerar med 
fysisk funktion. Det här projektet baseras på data från the Swedish National Study on Aging and Care 
in Kungsholmen (SNAC-K), en befolkningsstudie med 3,363 hemmaboende och institutionaliserade 
individer från 60 år och uppåt.  
Studie I. Vi skapade en kliniskt förankrad lista med 60 kroniska sjukdomar för att bedöma 
multisjuklighet hos äldre. Bland de 3,363 SNAC-K-deltagarna fann vi att 88.6% hade två eller fler 
kroniska sjukdomar, 73.2% hade tre eller fler kroniska sjukdomar och endast 11.4% hade ingen eller en 
kronisk sjukdom. Multisjuklighet borde ses som en pågående process av kroniska sjukdomars 
ackumulering som startar tidigt i åldrandet och fortsätter upp till mycket hög ålder.  
Studie II. Vi identifierade och följde utvecklingen av olika kluster av multisjuklighet över 12 år för 
2,931 SNAC-K-deltagare. Vid första mättillfället inkluderades 51.3% av deltagarna i ett av fem kluster, 
de resterande tillhörde en ospecificerad grupp eftersom de inte passade in i något sjukdomsmönster. 
Longitudinella övergångar mellan de kluster av multisjuklighet vi såg under 12 år berodde till stor del 
på kardiometaboliska riskfaktorer, utvecklandet av flera sjukdomar och mortalitet. 
Studie III. Vi undersökte sambandet mellan kardiovaskulär och neuropsykiatrisk multisjuklighet med 
förändringar av gånghastighet och förmågan av aktiviteter i dagligt liv (ADL) hos 2,385 SNAC-K-
deltagare över 9 år. Neuropsykiatrisk sjukdom, ensam eller i kombination med kardiovaskulär sjukdom, 
försämrade funktionen mest. Kardiovaskulär multisjuklighet var enbart associerat med en försämring i 
gånghastighet.  
Studie IV. Vi studerade samspelet mellan kardiovaskulär multisjuklighet och nedsatt funktion, samt 
mellan neuropsykiatrisk multisjuklighet och nedsatt funktion i relation till dödlighet (alla orsaker och 
orsaks-specifik) hos 3,241 SNAC-K-deltagare. Långsam gånghastighet ger ytterligare prognostisk 
information om dödlighet (alla orsaker och orsaks-specifik), utöver antalet av kardiovaskulära och/eller 
neuropsykiatriska sjukdomar.  
Slutsats. En standardiserad metod för att bedöma kroniska sjukdomar och multisjuklighet kan förbättra 
jämförelsebarheten mellan studier, miljöer och geografiska regioner. Att studera utvecklingen av 
multisjuklighet bland äldre kan bidra till bättre hypoteser om underliggande mekanismer och ge viktig 
prognostisk information. Kluster av multisjuklighet som innefattar kardiovaskulära och 
neuropsykiatriska sjukdomar är viktiga bestämmande faktorer för försämrad funktion och högre 
dödlighet. Användandet av en enkel och lätt mätning av nedsatt funktion, såsom gånghastighet, kan 
hjälpa hälsovårdspersonal att identifiera äldre personer med specifika kluster av kroniska sjukdomar 
med liknande behov, hälsoutveckling och prognos. 
Nyckelord: multisjuklighet; kluster av multisjuklighet; kronisk sjukdom; gånghastighet; nedsatt 
funktion; äldre; dödlighet; personcentrerad vård. 
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RIASSUNTO 
La multimorbilità, la presenza di due o più malattie nello stesso individuo, è una condizione frequente 
negli anziani, e si associa a numerosi eventi avversi. Nella presente tesi proponiamo una metodologia 
per la valutazione della multimorbilità nelle persone anziane, e impieghiamo la stessa per descrivedere 
l’evoluzione e la prognosi di diversi clusters di multimorbilità, nonchè per valutare in che misura cluster 
di malattie cardiovascolari e neuropsichiatriche impattino sulla funzione fisica. I dati derivano da uno 
studio di popolazione, lo Swedish National Study on Aging and Care in Kungsholmen (SNAC-K), che 
include 3,363 persone di 60 anni o più, che vivono al proprio domicilio o in istituzione.  
Studio I. In questo studio proponiamo l’utilizzo di una lista di 60 malattie croniche, selezionate su base 
clinica, per la valutazione della multimorbilità negli anziani. Applicando tale metodologia nei 3,363 
partecipanti di SNAC-K, l’88.6% e il 73.2% di essi risultava affetto rispettivamente da due o più e da 
tre o più malattie. Solo l’11.4% presentava zero o una malattia. Alla luce della facile saturazione di 
questi cutoff sarebbe preferibile considerare la multimorbilità come una misura continua che rispecchia 
l’accumulo di malattie che ha inizio in età adulta e continua sino ad età avanzate.   
Studio II. 2,931 partecipanti di SNAC-K sono stati suddivisi in cluster, in funzione dei pattern di 
multimorbilità espressi, e seguiti per 12 anni. Al baseline, 51.3% dei partecipanti è stato incluso in uno 
dei cinque cluster identificati. I restanti sono stati definiti come “non classificabili” poichè non 
caratterizzabili sul piano del pattern di malattie. Diversi fattori di rischio cardiovascolare, l’evoluzione 
e la complicazione delle stesse malattie, così come la morte, potrebbero essere responsabili della 
maggior parte delle transizioni tra cluster osservate durante i 12 anni di follow-up.  
Studio III. Abbiamo valutato in 2,385 partecipanti di SNAC-K la associazione della multimorbilità 
cardiovascolare e neuropsichiatrica con la variazione della velocità del cammino e il numero delle 
attività del vivere quotidiano intatte durante 9 anni. Le malattie neurospichiatriche, da sole o in 
combinazione con le cardiovascolari, esprimono rispetto ad altre il più forte impatto negativo sulla 
funzione. La multimorbilità cardiovascolare è associata selettivamente con la velocità del cammino.  
Studio IV: Abbiamo studiato come le malattie cardiovascolari e neuropsichiatriche interagiscono con 
la ridotta velocità del cammino nell’associazione con la mortalità in 3,241 partecipanti di SNAC-K. La 
ridotta velocità del cammino sembra conferire un valore prognostico aggiuntivo, in termini di mortalità, 
alla conta delle delle malattie cardiovascolari e/o neuropsichiatriche, ed in particolare rispetto alla 
mortalità per cause cardiovascolari.  
Conclusioni. L’utilizzo di una metodologia standardizzata per la valutazione delle malattie croniche e 
della multimorbilità può aumentare la comparabilità tra diversi studi, setting e regioni geografiche. 
Studiare l’evoluzione naturale della multimorbilità in persone anziane può aiutare a generare nuove 
ipotesi sui possibili meccanismi coinvolti e a fornire importanti informazioni di tipo prognostico. I 
cluster di malattie cardiovascolari e neuropsichiatriche emergono come un importante determinante di 
declino funzionale e mortalità. Infine, l’impiego di un semplice strumento per la valutazione della 
funzione fisica, quale la velocità del cammino, permette di identificare omogenei gruppi di individui 
che condividono simili traiettorie di salute e prognosi.   
Keywords: multimorbilità, cluster di multimorbilità, malattie croniche, velocità del cammino, 
disabilità, anziani, mortalità, medicina personalizzata. 
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摘要 
 
多重慢性疾病被定义为在同一人中存在两种或以上的慢性疾病；它在老年人群中很常
见，并伴有许多不良后果。在本论文中，我们提出了一种在老年人群中评估和测量多
重慢性疾病的方法，并以此来描述慢性疾病群的演变和预后，以及研究心血管性和神
经精神性多重慢性疾病对身体机能的影响。我们使用的数据来自Swedish National 
Study on Aging and Care in Kungsholmen （SNAC-K）队列。此队列是一个基于
3363名年龄60岁及以上居住在社区或收容机构的老年人的人群研究队列。 
 
课题一：我们基于临床上60种慢性疾病对老年人中的多重慢性疾病进行了评估。在3363名
SNAC-K参加者中，我们发现88.6％的人患有两种或以上慢性疾病，73.2％的人患有三种或以
上慢性疾病，而只有11.4％的人未患任何或只患有一种慢性疾病。因此，多重慢性疾病应被
视为一个，始于衰老早期至生命晚期的慢性疾病的持续积累的过程。 
 
课题二：我们用2931名患有两种或以上慢性疾病的SNAC-K参加者的12年随访数据，分析并追
踪了多重慢性疾病群的演变过程。在基线时，51.3％的参加者属于五个疾病群中的任意一
个，而剩余的参加者都属于一个非特定疾病群体，由于没有任何一种疾病模式能够将他们划
分在一起。心脏代谢风险因素、几种疾病的演变、以及死亡可能在12年随访间驱使了大部分
多重慢性疾病群的演变。 
 
课题三：我们用2385名SNAC-K参加者的数据研究了心血管性多重慢性疾病和神经精神性多重
慢性疾病与9年随访中步行速度变化和日常生活活动之间的相关性。单独或伴有心血管疾病
的神经精神疾病对身体机能衰退有最为不利的影响。心血管性多重慢性疾病仅与步行速度下
降相关。 
 
课题四：我们用3241名SNAC-K参加者的数据研究了心血管性多重慢性疾病与身体机能障碍的
交互作用，以及神经精神性多重慢性疾病与身体机能障碍的交互作用，对全因死亡率和死因
别死亡率的影响。我们发现，除心血管和/或神经精神疾病数量以外，较慢的步行速度能为
全因死亡率和死因别死亡率提供额外的预后信息。 
 
结论：使用标准化方法评估慢性疾病和多重慢性疾病可以提高不同研究、人群、和地理区域
间的可比性。研究老年人群种多重慢性疾病的自然演变可助于更好地研究潜在机制并提供重
要的预后信息。心血管和神经精神疾病在内的多重慢性疾病群是身体机能衰退和高死亡率的
主要决定因素。最后，采用简单易用的身体机能测量方法（如步行速度）可以帮助专业医疗
人员在老年人群中识别具有相似的需求、健康轨迹、和预后的慢性疾病患者。 
 
关键词：多重慢性疾病；多重慢性疾病群；慢性疾病；步行速度；失能；老年人；死亡率；
个性化医疗 
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1 INTRODUCTION  
1.1 HEALTH AND AGING 
1.1.1 The aging population 
Individuals live longer than in past decades as a result of improvements in the biomedical 
sciences and public health, and the development of modern preventive strategies and medical 
treatments. Together with dropping fertility rates, this has resulted in a dramatic increase in the 
absolute number and prevalence of older adults (2). By 2050, the percentage of the world's 
population over 60 years of age will nearly double, compared with 2015, increasing from 12% 
to 22%. In Sweden, by the same year, people older than 60 years will represent 30% of the 
population (3).  
This massive expansion, especially of those older than 85 years, coupled with the contraction 
of the active-age population, poses a series of challenges for worldwide public financial, 
welfare, and health-care systems. Changes in the way health care is delivered and human and 
economic resources are allocated will soon be required (2). In this scenario, a strategy toward 
sustainability includes improving older adults’ health, thus promoting their continued vitality 
and active participation in society for as long as possible.   
1.1.2 Defining health in older age 
If living longer was the main accomplishment of the past century, living healthier as long as 
possible is the current goal. Personal attitudes change during life, making people value different 
activities and aspirations at different ages. Older adults value the following capabilities: 
maintaining mobility, tightening relationships, coping with basic needs, being able to make 
decisions, and contributing actively to society. According to the World Health Organization 
(WHO), health in older age is a holistic attribute that enables older individuals to achieve goals 
that are important to them. Rather than the mere absence of disease, it is the ability to preserve 
and enhance those aspects of life that defines a good perception of health in older adults (2, 4). 
Hence, the maintenance of physical and mental functions is essential to accomplishing life 
goals in all ages (4). However, older people are more likely to experience circumstances that 
undermine their functioning and limit their ability to fully carry out everyday activities, 
potentially leading to disability. Several conditions, including disease and socioeconomic 
disadvantage, contribute to accelerating the progressive functional decline experienced by 
older people. Buffering the negative impact of these factors on function, and compressing 
disability to the very last period of life, are the main goals of medical and public health 
interventions aimed at improving older adults’ health (2, 4).  
1.1.3 Health heterogeneity and complexity 
Aging is a dynamic, multifaceted, and complex phenomenon, and its effects are reflected in the 
phenotypic heterogeneity of older people and their health (5). Lifelong exposure to 
combinations of intrinsic and environmental factors set the pace of aging (6). The aging process 
is accompanied by the accumulation of biological deficits that undermine the homeostatic 
balance of the organism, progressively leading to physical and cognitive impairment. Such 
impairment characterizes disadvantageous phenotypes predisposed to develop disability and 
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earlier mortality (7). This process is characterized by varied health trajectories and proceeds at 
varied speeds in different individuals. The concept of frailty identifies the tendency of 
phenotypically old persons to develop adverse outcomes and experience rapid changes in their 
health status (8). Chronic disease is among the most important determinants of frailty. To a 
certain extent, and with exceptions, disease may be thought of as the result of accrued biological 
impairment that, beyond certain thresholds, configures precise nosological entities (9). 
Notably, in older people, to be affected by multiple chronic diseases (multimorbidity)—rather 
than a single disease—represents the norm.  
At an older age, many individuals enjoy good physical and mental functioning; others, 
however, may require assistance to accomplish daily basic activities at a younger age than their 
counterparts. Interestingly, frailty can occur also in the absence of a high disease burden (5, 10-
13). One meta-analysis has shown that at least seven in ten frail older people suffer from 
multimorbidity, but less than two in ten older people with multimorbidity also exhibit frailty 
(9). On the one hand, these findings support the idea that a higher disease burden is associated 
with higher frailty. On the other, they confirm that most people with multimorbidity remain 
well functioning even in older ages. Understanding the determinants of frailty and functional 
impairment in the absence of overt disease and multimorbidity represents an interesting 
research question for future studies. 
Assessing the health and care needs of older persons requires taking into consideration not only 
the burden of specific diseases but also the extent to which they interact and impact on function 
(2, 4, 14, 15). This holistic approach—as opposed to the unidimensional assessment of disease 
status—is the cornerstone of geriatric medicine, and is shown to better predict survival and 
other health-related outcomes in older adults (5). Health-care models that consider and manage 
the complex needs of older age in a multidimensional and integrated way have been shown to 
be more effective than services tailored merely to individual diseases (16-18). 
The complexity and multidimensional features of health in older people represent major 
sources of uncertainty at several levels of the clinical decision process, especially when facing 
multimorbidity, frailty, or approaching end of life (19-22). A health system centered on the 
treatment of single diseases and the lack of guidelines tailored to patients with multifaceted 
needs drive this uncertainty (23). Currently, clinicians have limited scientific support in 
approaching complex patients and explaining the potential benefit and harm of treatments (1). 
In the era of personalized medicine, the identification of clinically relevant health profiles may 
help care systems build personalized preventive and intervention care paths (23-26). As 
hypothesized later in this thesis, clusters of multimorbidity may help detect groups of people 
with similar care needs and prognoses. Untangling the relationship between disease and 
function and investigating their prognostic meaning ultimately represents a step toward 
personalized medicine (1). 
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1.2 THE DISEASE BURDEN IN OLDER AGE 
1.2.1 Epidemiology of multimorbidity 
The concurrent presence of multiple diseases in the same individual defines the condition of 
multimorbidity and is usually considered a distinctive syndrome of aging. Depending on the 
sample population and its operationalization, multimorbidity prevalence ranges from 55% to 
98% in older people (27). In the Swedish National Study on Aging and Care in Kungsholmen 
(SNAC-K), source of the present thesis, the prevalence of multimorbidity (i.e., two or more 
diseases) is as high as 89% (figure 1). This makes multimorbidity a more common condition 
than any other single disease and consequently the most frequently encountered one in clinical 
practice, including primary care (27, 28). According to projections, 26% of the total United 
States population will live with multimorbidity by 2030 (29). In recent decades, both the 
amount and prevalence of the population with multimorbidity increased, with the sharpest 
increment in more recent generations of older adults (30). These demographic shifts, along 
with the application of more sensitive diagnostic tools and procedures, are the main drivers of 
this phenomenon (31).    
Multimorbidity is associated with a number of negative health-related outcomes, including 
poor quality of life and an intense utilization of health-care services (12, 27, 32). According to 
a meta-analysis of 26 observational studies, having two or more diseases, or three or more 
diseases, was associated with a pooled relative hazard ratio for mortality of 1.73, and 2.72, 
respectively. On average, each additional disease increased the mortality rate by 40% (33). The 
result of the interaction of multiple coexisting illnesses is hard to predict and may lead to 
completely new clinical phenotypes (e.g., geriatric syndromes) (1, 34). The negative outcomes 
related to multimorbidity are often more significant than the simple sum of the effects of single 
diseases. In a large study involving 1.2 million participants, the negative impact on surviving 
Figure 1. Percentage distribution of the number of chronic diseases by age group in the Swedish 
National Study on Aging and Care in Kungsholmen (SNAC-K; N = 3363). Data source: Journals 
of Gerontology: Medical Sciences 2017 (1). 
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co-occurring cardiometabolic diseases was found to be multiplicative (35). Several studies 
showed an association between multimorbidity and clinical and functional outcomes, such as 
hospitalization, poorer quality of life, shorter survival, disability, physical and psychological 
distress, and higher health-related costs (5, 10, 12, 27, 36).  
1.2.2 Aging and multimorbidity 
Age, female sex, socioeconomic deprivation, and low educational attainment represent the 
most important known risk factors for multimorbidity (31, 37). However, the development of 
multimorbidity cannot be entirely explained by individuals’ sociodemographic traits, which 
indeed are more likely to be proxies of underlying phenomena, directly or indirectly linked to 
multimorbidity. In this regard, a handful of sparse, longitudinal, epidemiological studies 
identified a group of clinical risk factors for the development and progression of multimorbidity 
(31).  
Obesity has been associated with an earlier onset of multimorbidity, both in males and females 
(38). Several mechanisms may explain such association. Overweight and obesity may affect 
people’s functional abilities and fitness, reducing mobility and promoting social isolation. At 
the same time, adipose tissue is a source of inflammatory cytokines and promotes insulin 
resistance, both of which represent risk factors for the onset of cardiovascular and 
noncardiovascular diseases (39). Interestingly, in obese older adults, unintentional weight loss 
has also been linked with multimorbidity. The development of anemia and kidney dysfunction 
partially explains such association (40). In several studies, a low level of physical activity and 
a sedentary lifestyle have been associated with the incidence of a number of age-related 
diseases, including cardiovascular diseases, dementia, depression, and cancer (41). Our grasp 
of risk factors for multimorbidity is probably incomplete, given the paucity of studies on the 
topic, and further studies are needed to shed light on such mechanisms (31).   
The aging process and multimorbidity share the same foundation. This is supported by the 
epidemiological observation that age is the most important risk factor for the development of 
multimorbidity (7, 30, 31, 42). Age is the signature of the stochastic damage—and subsequent 
activation of compensatory mechanisms—that accumulates over an entire life. Disease may be 
seen as the phenotypic manifestation of such accrued damage and depletion of reserves. Aging 
and multimorbidity mutually interact, speeding each other’s progression (1, 31). In this regard, 
a faster accumulation of chronic disease has been proposed as a model of accelerated aging 
(30, 43).  
Insight into the putative biomolecular causes of aging and multimorbidity is enhanced by 
emerging evidence that highly circulating levels of inflammatory cytokines, a condition of 
chronic low-grade inflammation known as inflammaging, has been associated with 
multimorbidity both cross-sectionally and longitudinally (30, 44). Inflammation and 
multimorbidity result from the damages accumulated over time in organs and physiological 
systems. Such damage challenges individuals’ biological reserve capacity and resilience to 
stressors (30, 43). Diseases are typically recognized when organ and system dysfunction, and 
the underlying molecular determinants, exceeds a clinically relevant threshold. These changes 
lead to cellular damage and are usually referred to as the hallmarks of aging (figure 2). Such 
hallmarks may be grouped into primary (gene and protein instability, telomere attrition, 
epigenetic changes), secondary (nutrient sensing dysregulation, mitochondrial dysfunction, 
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cellular senescence), and integrative (stem cell exhaustion and impaired intercellular 
communication) mechanisms (45). Primary hallmarks thus represent the initial underlying 
damages responsible for the aging process, secondary hallmarks are compensatory responses 
to the initial damage, and integrative hallmarks contribute directly to aging-related phenotypes, 
including multimorbidity (43, 45). Interestingly, defect accumulation is not only the foundation 
of the aging process and the fertile ground from which diseases arise, but is also integral to the 
“frailty syndrome” concept, which will be addressed later in this thesis (8).  
 
 
Experimental studies have demonstrated that an extended life-span may be reached by delaying 
the onset and progression of multiple diseases and the subsequent functional decline (46, 47). 
It is therefore plausible that postponing or preventing the onset of multimorbidity could slow 
down the functional decline associated with aging. At the same time, intervention focused on 
the underlying mechanisms of aging could reduce the number of chronic conditions and the 
speed of their accumulation, resulting in a significant improvement in people's health (47). 
Caloric restriction and multidomain intervention suggest promising strategies in this regard 
(48, 49). In particular, a regimen of caloric restriction coupled with proportionate nutrient 
intake was shown to protect against central obesity and reduce the incidence of diabetes, 
hypertension, and cardiovascular events (50). Notably, the Targeting Aging with Metformin 
(TAME) trial will be the first randomized controlled trial (RCT) that will test the effectiveness 
of a drug, metformin, to slow the aging process. In the TAME trial, the accumulation in time 
of age-related diseases was identified as the outcome of interest (46).  
1.2.3 Clusters of multimorbidity 
While earlier studies in multimorbidity considered the pure count of concurrent diseases, with 
or without the use of cutoffs, more recent efforts converge on the study of a more systematic 
and homogeneous combination (that is, patterns) of chronic conditions, or associative 
Figure 2. Underlying hallmarks of aging and multimorbidity.  
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multimorbidity (51). Epidemiological studies consistently show that chronic diseases tend to 
cluster in a person according to specific patterns. As many as 97 specific clusters of chronic 
diseases have been identified in a systematic review published in 2014 (51). Most consistently 
detected are cardiovascular, neuropsychiatric, and musculoskeletal disorders (51). The 
systematic clustering of chronic diseases may be related to common pathophysiological 
mechanisms or risk factors. On the one hand, this could indicate genuine etiological links 
between the conditions, opening up new research avenues. On the other hand, some clustering 
could be spurious, attributable mainly to a methodological pitfall, namely, the way diseases 
have been assessed and clustered in an individual study (1, 52). Another explanation of the 
inconsistency across studies may be that multimorbidity clusters are likely not to be static, but 
rather to evolve over time, and are conditioned by the modifying pressure of contextual factors 
and death. Indeed, very few studies have investigated multimorbidity clusters from a 
longitudinal perspective, and most of them were compromised by the use of administrative data 
sources or self-reported diagnoses, restricted lists of chronic diseases, and short observation 
periods (53-58). Notably, all these studies focused on clusters of chronic diseases, instead of 
clusters of people characterized by specific multimorbidity patterns. Focusing on people 
instead of diseases is more in line with the principle of patient-centered care and may provide 
information that would help physicians and health-care systems to move faster toward models 
of personalized medicine (23, 24, 26).   
In the present thesis we have focused our attention on the clusters of multimorbidity featured 
by cardiovascular and neuropsychiatric chronic disease. Cardiovascular and neuropsychiatric 
disease is the most prevalent and burdensome chronic condition in the older population and is 
among the major determinants of the global burden of disability-adjusted life years (DALYs) 
(59). Cardiovascular and neuropsychiatric diseases account respectively for 30% and 7% of the 
years that older people spend with disability (59). Beyond being the most prevalent condition 
encountered in this age group, cardiovascular and neuropsychiatric disease share common risk 
factors, stem from the same pathophysiological pathways, and may influence each other (both 
in terms of etiology and severity). An indirect proof of such cluster-specific homogeneity is 
that different diseases are often treated with the same medication. For instance, angiotensin-
converting enzyme inhibitors, widely prescribed in older adults, find multiple indications in 
cardiovascular medicine. This is attributable to their pleiotropic properties, which encompass 
the ability to lower blood pressure, slow myocardial remodeling in heart failure and ischemic 
heart disease, and reduce the recurrence of atrial fibrillation (60).  
Beyond cluster specificity, cardiovascular and neuropsychiatric diseases are likely to interact 
with each other. For instance, mental disorders may stem from heart disease, as in the case of 
dementia in people with heart failure and atrial fibrillation (61, 62). Similarly, heart disease can 
be triggered by mental conditions, as in the case of arrhythmias that are more frequently 
diagnosed in people with anxiety and related disorders. Finally, there is sparse evidence of an 
interplay among diseases of different systems; better understanding of the body-mind 
interaction has the potential to uncover novel preventive and prognostic strategies.  
1.2.4 Clinical challenges of multimorbidity 
Available guidelines for the treatment and management of specific chronic diseases are 
exclusively based on the results of randomized controlled trials carried out in selected sample 
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1.2.4 Clinical challenges of multimorbidity 
Available guidelines for the treatment and management of specific chronic diseases are 
exclusively based on the results of randomized controlled trials carried out in selected sample 
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populations. Complex older people, affected by multiple diseases and with social and physical 
frailty are either severely underrepresented, or outright absent, in these studies (63, 64). As a 
consequence, a huge gap exists between official recommendations provided by the scientific 
community and the real-world clinical complexity encountered every day by clinicians and 
other health-care professionals (23, 24, 26, 64, 65). 
Recent attempts have been made to provide official guidelines for people with multimorbidity 
(66-69). The primary focus of these guidelines has been on patients’ quality of life rather than 
increasing survival or the accomplishment of disease-specific targets, such as reaching optimal 
blood pressure or cholesterol values. Moving the aim away from the treatment of a single 
disease and toward a more holistic approach, these recommendations recognize the role not 
only of health-care professionals but of patients with multimorbidity and caregivers. Five key 
principles have been identified in systematic review and expert consensus on available 
guidelines for the management of multimorbidity and polypharmacy in complex older adults: 
(a) identifying the target population; (b) assessing the interactions of disease and medication; 
(c) taking into account patients’ preferences, priorities, and goals; (d) individualizing the 
intervention; and, (e) monitoring and following up patients over time (17, 66). Given the risk 
factors involved in developing multimorbidity and that the biological bases of the condition are 
far to be fully understood, guidelines for the actual treatment and prevention of multimorbidity 
are nonexistent; thus far, only indications for its management have been provided.  
Multimorbidity poses a number of managerial and therapeutic challenges (68). Polypharmacy, 
usually defined as the use of five or more medications, is the direct result of the application of 
single-disease guidelines to individuals suffering from multiple chronic diseases (figure 3) (70-
74). Polypharmacy has been associated with an increased risk of developing iatrogenic illness 
and functional decline (both physical and cognitive), which further increases the level of 
clinical complexity in people with multimorbidity (65). Overlooking the possibility of 
triggering drug-disease interaction is one of the most relevant threats of prescribing medication 
to multimorbid older people (64). Pharmacokinetics and pharmacodynamics are affected by 
the aging process and may strongly vary between patients affected by one disease and complex 
patients presenting multimorbidity (75). Beyond drug-disease interactions, drug-drug 
interactions are also a consequence of polypharmacy.  
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The side effect of a given medication is often interpreted as a new symptom, and is then treated 
with additional medication, generating a vicious circle referred to as a prescribing cascade. 
Medication review and deprescribing are two important components of managing older people 
with multimorbidity (76). Unfortunately, little evidence has been produced thus far to support 
such practices (77). Some studies show that involving a clinical pharmacist and using a 
computerized prescription support system during medication review and reconciliation for 
older patients with multimorbidity can be crucial to improving the quality of prescription and 
patients’ experience (19, 78).  
In 2018, the results of the largest pragmatic RCT on the management of people with 
multimorbidity were published. In this study, the authors tested the efficacy of a patient-
centered approach, based on the assessment of several health dimensions, depression, and 
medication—a so-called 3D approach—carried out in 33 United Kingdom primary-care 
practices. Overall, 1,546 adults with three or more chronic conditions were randomized to 
receive either the 3D intervention or the usual care. After 15 months of the randomization, the 
authors could not demonstrate any improvement in patients’ quality of life, chosen as the 
primary outcome of the study (79). Several factors may explain the negative result. First, the 
threshold of three diseases may not be clinically relevant. Several studies have shown that older 
people can experience a good quality of life despite a high disease burden (5, 10, 36, 80). 
Second, targeting multimorbidity is probably not enough. In this regard, a more holistic and 
multidimensional approach toward complex patients may improve the identification of the at-
risk population. The simultaneous assessment of dimensions including frailty, physical 
functioning, cognitive status, and social disadvantage could help in identifying subgroups of 
patients with multimorbidity who are more susceptible to the intervention (1, 9, 34, 81, 82). 
Figure 3. Association between number of chronic diseases and number of drugs in the Swedish 
National Study on Aging and Care in Kungsholmen (SNAC-K; N = 3363). Data modified from 
Journals of Gerontology: Medical Sciences 2017 (1). 
 .  
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1.2.5 Public health challenges of multimorbidity 
Multimorbidity is among the major triggers of intense health-care-service utilization. Health-
care systems nonetheless fail to address complex older adults with multimorbidity, because 
robust scientific evidence that can guide new models of care is lacking (2). Consequently, 
health-care spending keeps increasing, but the clinical needs and preferences of frail and 
multimorbid patients remain largely unattended (1).  
National health-care systems are currently designed to respond to acute health episodes, 
neglecting that the health status of older adults fluctuates over time, strongly influenced by 
socioeconomic and other nonclinical domains. Nowadays, medicine tends to prioritize the use 
of technology and increasingly heads toward hyperspecialization. This directly contradicts the 
strengthening of primary and highly coordinated care, which has been recently advocated for 
the effective management of the increasing number of people with multimorbidity. Finally, 
despite many clinicians knowing that effective care of older people with multimorbidity cannot 
disregard a person-centered approach, the real-world gap between practice and patient is 
growing. Health-care models are left with expensive, burdensome, or unclear benefits and 
potential harm and are economically unsustainable (83).  
Several steps need to be taken to build effective care paths for people with multiple chronic 
diseases. The steps recommended for the clinical management of older people with 
multimorbidity may also promote the implementation of high-performance health-care 
systems. Based on patient-centered medicine that detects older adults’ care needs in a timely 
fashion, they take into account the complexity of the clinical picture, empower patients and 
their families, and guarantee continuity of care (17).     
1.2.6 Methodological aspects of multimorbidity assessment 
Recent decades have produced extensive literature on the topic of multimorbidity, yet a number 
of methodological weaknesses limit the generalizability—and sometimes the interpretation—
of these findings. While there is strong agreement on the definition of multimorbidity as the 
presence of two or more chronic diseases in the same person, it remains unclear which diseases 
should be assessed, how many diseases should be included in the count, and how diseases 
should be assessed. The lack of indication depends on the vast methodological heterogeneity 
encountered in these studies. According to a systematic review published in 2011 of 39 articles, 
the number of diseases assessed in the retrieved studies ranged from 4 to 102, most of them 
based on self-reported information (84). The diseases considered in these studies were usually 
identified according to predefined criteria, such as prevalence in the older population, risk of 
adverse health-related events, or likelihood to be treated. Finally, it is not uncommon that 
researchers choose a list of candidate diseases for pragmatic reasons, such as the availability of 
information in a given data set. The heterogeneity of the methodology is reflected primarily in 
the wide range of multimorbidity prevalence estimates reported, from 55% to 98% in the 
abovementioned systematic review. In addition, as mentioned earlier in this chapter, the varied 
ways in which diseases are assessed may be responsible for the high number of unique 
multimorbidity clusters identified in the literature (51).    
In addition to the challenges of selecting specific diseases, their counts, or data sources, the 
actual definition of chronic disease and the level of aggregation and categorization of chronic 
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conditions for the operationalization of multimorbidity impose additional limitations. In most 
studies of multimorbidity in older people, a univocal definition of chronic disease is missing. 
Characteristics such as duration, reversibility, course, treatment, and consequences are usually 
considered in the definition of chronic condition, yet these features are used in a sparse and 
inconsistent fashion across studies. It is not uncommon for studies to categorize the diseases of 
interest differently, whereby the same nosological entity may either be considered individually 
(e.g., atrial fibrillation) or operationalized as part of a more comprehensive category (e.g., heart 
disease). These elements of variability further contribute to affect the clinical, 
pathophysiological, and epidemiological interpretation of such studies (1).  
Developing ad hoc indications for the operationalization of multimorbidity in older adults, both 
in clinical and research settings, represents a priority of this research area. Such a tool will 
enable high quality and comparable research, which will assist physicians and health-care 
systems in improving the prognosis, diagnostic paths, treatment, and care of older people with 
multimorbidity. 
1.2.7 Knowledge gaps antecedent to this thesis 
In the last two decades, a high number of studies have investigated the occurrence of 
multimorbidity and its impact on different health-related outcomes. Unfortunately, very few 
have contributed solid evidence based on a sound methodology with a clear definition of 
chronic disease and, most importantly, a robust and reliable, clinically driven operationalization 
of multimorbidity. Consequently, findings from different studies are hardly comparable and 
often contradict each other. The establishment of rigorous and scientifically valid 
recommendations for the appraisal of multimorbidity in older adults may help answer many of 
the questions remaining open or dubious in this field.    
Another important research gap arises from the scarce relevance given until now to the 
longitudinal evolution of multimorbidity, and the subsequent effects of such changes on older 
individuals’ health. Multimorbidity is a dynamic phenomenon, and describing it through static 
(i.e., cross-sectional) snapshots may run the risk being too reductionist in mapping its 
underlying complexity. Longitudinal studies that describe the evolution of multimorbidity over 
time, with its potential driving factors, can improve understanding of the pathophysiology of 
multimorbidity, eventually increasing the potential of preventive strategies. 
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1.3 FUNCTION IN OLDER AGE 
1.3.1 Functional decline with aging 
Preserving the ability to move around and carry out daily activities are two of the most valued 
goals of older adults. The integrity of mental and physical functioning is essential to 
accomplishing these tasks. When either one or both of these functions are impaired beyond a 
certain threshold, people are no longer able to maintain their independence, with consequences 
at personal, familial, and societal levels (5, 10, 36, 80, 85, 86).  
Aging is associated with a decline in most physiological systems that culminates in limiting 
physical capacity. Muscle strength and physical performance peak in an early stage of 
adulthood, usually between the third and fourth decades of life, as a result of the developmental 
plasticity of humans evident during the first decades of life. During the fourth decade, these 
functions start their progressive decline (87). According to an Italian-Taiwanese collaborative 
study involving community-dwelling adults, muscle strength, measured through the handgrip 
test, and physical performance, assessed by the chair stand test, start to decline at the age of 45, 
after reaching a plateau, in both women and men (88). To a certain extent, this decline may be 
physiological, although a fast decline in physical function can also be considered a sign of the 
accelerated aging that precedes several negative health outcomes (86, 89). If death does not 
occur, disability and dependence in the activities of daily living are usually the results of the 
decline in cognitive and physical function. 
1.3.2 Functional assessment 
Several measures have been proposed to assess physical function in older adults, including 
strength tests (e.g., handgrip strength), balance tests (e.g., one-leg balance test), performance 
tests (e.g., walking speed), or combinations thereof (e.g., short physical performance battery). 
All these measures have been consistently shown to predict adverse outcomes in older adults 
and perform well in detecting at-risk individuals, also in clinical settings. Among the suggested 
tests, walking speed appears to be the most convenient and informative measure of physical 
performance in older adults, both in research and clinical practice.  
1.3.2.1 Walking speed 
Walking speed is a comprehensive and commonly used measure of mobility. It can be easily 
assessed in clinical settings and is highly predictive of a number of health-related outcomes. In 
accordance with the International Academy on Nutrition and Aging (IANA), the assessment of 
usual gait speed represents a “single, more reliable, valid, sensitive (not necessarily specific), 
cheap, safe, quick, and simple tool” able to identify older people at risk of negative events (90). 
Older people with impaired walking speed, and those experiencing a more rapid decline in 
walking speed, exhibit more care needs, incident disability, and higher mortality rates (89-92). 
Interestingly, impaired walking speed is also associated with faster cognitive decline and higher 
incidence of dementia. Thus, walking speed can be considered a relevant metric and 
determinant of health in older age (5, 10). 
In older people, walking speed is the result of one’s genetic predisposition and its interaction 
with lifelong exposure to internal and external factors. Walking is an energy-demanding 
activity that requires a fine command of the central nervous system (CNS), the integrity of a 
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number of body systems and organs (e.g., cardiovascular and musculoskeletal), and the support 
of several sensorial functions (e.g., vision and hearing; figure 4). Walking speed decline is the 
result of both clinical and subclinical impairment accumulating across the abovementioned 
structures and functions. For these reasons, it is deemed a reliable summary measure of 
biological age, and its faster decline is a sign of accelerated aging and frailty (31, 91, 93).  
 
 
 
 
 
Figure 4. Body systems involved in the maintenance of gait speed and possible determinant 
factors. Data modified from Experimental Gerontology 2019 (in press). 
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Several factors may affect walking speed. First, demographic and lifestyle-related conditions, 
such as female sex and sedentarism, may affect walking speed (94-96). Second, both acute and 
chronic conditions may impair walking. These include systemic (e.g., fever, pain) or organ-
specific conditions (e.g., cardiovascular events, osteoarthritis) (93, 97-99). Finally, a number 
of external factors may affect gait speed, including medication (e.g., anticholinergics) or the 
use of walking aids (100-106). Untangling the role played by each of these conditions remains 
challenging. 
Several cutoffs have been suggested to define slow walking speed. Among them, cutoffs of 
0.8 m/s and 1.0 m/s are the most frequently used. Studenski et al., in a large study (N = 34,485) 
of nine cohorts of community-dwelling older adults, showed that walking speed exceeding 
0.8 m/s was associated with an increase in life expectancy above median levels (91). 
Interestingly, as shown in the Health, Aging and Body Composition Study, a more rapid 
decrease in walking speed is associated with shorter survival, independent of baseline status 
(89). 
1.3.2.2 Disability 
The most common way to assess disability is by evaluating the impairments an individual has 
accumulated in six basic activities of daily living (B-ADL) and in eight instrumental activities 
of daily living (I-ADL) (107). B-ADL relate to the ability to move around, eat, and take care 
of personal hygiene. Older adults are usually able to maintain B-ADL until late life, and start 
to lose them as severe physical and mental impairments occurs. On the other hand, I-ADL 
relate to more complex activities, encompassing the ability to go out independently, manage 
finances, and take care of the house. In contrast to B-ADL, I-ADL become impaired earlier in 
old age, and require the integrity of more complex cognitive functions and fitter physical 
functions. Impaired B-ADL and I-ADL are highly predictive of a number of negative health-
related outcomes, including hospitalization, institutionalization, and shorter survival. Finally, 
people with disabilities consume most social care services (108).         
1.3.3 Complementarity of measures of physical function 
Walking speed and other parameters of physical function, including measures of disability, 
follow different trajectories for different individuals during the life course. Timely detection of 
the modifiable risk factors that lead to a faster functional decline may help prevent disability 
later in life, eventually improving quality of life of older adults. According to a Swedish 
population-based study, and in line with previous studies, walking speed starts to decline at 
a constant pace from midlife until very old age (10, 89, 109). Dependency in I-ADL and in B-
ADL, however, starts to become evident only after ages 80 and 85, respectively (10). This 
suggests that walking speed may help to detect further development of disability at an early 
stage. In other words, as the discriminative power of each of these metrics changes with age, 
their assessment may provide different information during different periods of life (5). Above 
all, assessing more than one of these metrics will provide a broader overview of one’s 
functional status and prognosis.  
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1.3.4 Frailty 
Although investigating the role of frailty as a determinant of health in older people was not 
among the aims of this thesis, its multiple points of contact with both multimorbidity and 
functional ability demand an introduction. Frailty is defined as a condition of increased 
susceptibility to internal and external stressors, and reflects the faster aging of multiple organs 
and systems (8, 110). The concept of frailty as a measure of biological age appeared in geriatric 
medicine during the last two decades and soon obtained consensus from both clinicians and 
researchers. Frailty is a common finding in older adults. A systematic review of 21 community-
based studies published in 2012 that encompassed more than 60 thousand individuals found 
that the prevalence of frailty in the general population varied between 4.0% and 59.0%, 
depending on the study population and operationalization of frailty. The review reported an 
overall weighted prevalence of frailty of 10.7%, which increased with older age and in women 
(111).  
Despite wide agreement on the theoretical definition of frailty, less consensus exists on its 
operationalization. This lack of consensus has led to a multitude of different tools for the 
screening and assessment of frailty. Some researchers assert that a reliable operationalization 
of the concept of frailty should be founded on its ability to predict both the natural history of 
older adults’ health and the response to specific therapeutic interventions (8). So far, the two 
most successful models of frailty have been the frailty phenotype, proposed by Fried et al., and 
the frailty index, proposed by Rockwood et al.  
Fried et al. proposed a conceptual framework and an operationalization of physical frailty for 
the first time in 2001. In this proposal, physical frailty is diagnosed in the presence of at least 
three of the following items: unintentional weight loss, self-reported exhaustion, low energy 
expenditure, slow gait speed, and weak grip strength (112). Older people exhibiting one or two 
of these criteria are considered prefrail, and those with none are identified as robust. Using the 
data from the Cardiovascular Health Study, according to Fried et al., 7% of the study sample 
was considered frail, 47% prefrail, and 46% robust. In longitudinal analyses, both in this and 
other studies, the frailty phenotype was shown to reliably predict increased risk of several 
negative health outcomes, including hospitalization, disability, and shorter survival (113-115).  
Conceptually different from the construct of physical frailty, the Rockwood’s frailty index is 
based on the ratio between the number of deficits expressed by an individual and the number 
of those assessed. The frailty index assumes values between zero (no frailty) and one (100% of 
deficits present). In the original proposal, 70 deficits, including symptoms, signs, abnormal lab 
tests, diseases, and disabilities, were used to compute the score (116). This model of frailty is 
clinically attractive, given that it allows consideration of frailty on a continuum rather than as 
a binary outcome (117, 118). The ability of the frailty index to predict negative health outcomes 
has been demonstrated in numerous studies (113).  
While many tools assess frailty, the prognostic value of the concept has been repeatedly 
demonstrated across populations and instruments. The multidimensional and comprehensive 
assessment of function embedded in each of these tools may explain this. However, one of the 
main obstacles to translating research findings to clinical practice is the difficulty of including 
complex and time-consuming assessments in daily clinical practice. For this reason, many 
agree that the measurement of walking speed may be a practical and exhaustive way of 
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assessing frailty. In several clinical studies it allowed a reliable stratification of the clinical risk 
of specific conditions related to procedures and interventions (119-121) .   
1.3.5 Multimorbidity and functional decline 
Apart from a few exceptions (122), the association between multimorbidity and poor physical 
function in older adults was demonstrated in several cross-sectional and longitudinal studies 
(12, 123, 124). According to a population-based study by Aarts et al., functional impairment 
from multimorbidity persists over time and often shows further worsening (125). Jindai et al. 
showed that, in older individuals, the association between multimorbidity and functional 
limitation is strengthened in older age (>75) and in females. If the modifier effect of older age 
is expected, given the reduced resilience of the oldest old individuals, the effect of the sex of 
the individual requires further investigation (126).  
Sparse evidence suggests that, in older individuals, specific clusters of chronic disease exert a 
differential impact on physical function and disability (27). Some combinations of disease may 
be more detrimental than others in their effect on physical function as the result of mechanisms 
stemming from the dysfunction of various bodily systems (127, 128). Given the focus here on 
the health impact of cardiovascular and neuropsychiatric multimorbidity, published evidence 
of cardiovascular and neuropsychiatric clusters of multimorbidity and functional decline in 
older adults is reported. Beyond one of the constituent papers of this thesis, four studies 
investigated the association between multimorbidity clusters and disability. Jackson et al. 
reported that, in a sample of 7,270 older women participating in the Australian Longitudinal 
Study on Women’s Health, cardiovascular and neuropsychiatric clusters of chronic disease—
but not musculoskeletal—were significantly associated with more dependence in B-ADL and 
I-ADL (129). Koller et al., in a study based on administrative data from 115,203 older 
individuals, reported a significant association between all the main multimorbidity patterns 
identified in the study and dependency. Notably, the cluster including neuropsychiatric diseases 
showed the strongest association with dependency (130). Quiñones et al., using longitudinal 
data from the United States on nearly 9,000 older individuals, found that the multimorbidity 
cluster composed of  symptoms of depression, arthritis, and hypertension predicted disability 
better than other multimorbidity clusters (131). This result was replicated in another study 
based on 4,000 older adults from the Medicare database in which the copresence of physical 
and mental disorders (especially cognitive impairment and dementia) was linked with a higher 
likelihood of disability, relative to reporting several exclusively physical conditions (132). 
The abovementioned studies provide several insights into the association between 
multimorbidity clusters and function in older people. First, cardiovascular and neuropsychiatric 
diseases represent the most common conditions in older adults and feature as recognizable 
clusters of multimorbidity. Second, these two disease groups are independent predictors of poor 
functioning. Third, neuropsychiatric diseases show a stronger impact than cardiovascular 
diseases on functional outcomes. Finally, the presence of neuropsychiatric diseases seems to 
exacerbate the negative consequences of other individual conditions, suggesting the existence 
of a biological interaction among such morbidities. 
However, several issues inhibit the generalizability of the results of these studies, limiting the 
possibility of drawing definitive conclusions about the relationship between cardiovascular and 
neuropsychiatric multimorbidity and functional decline. First, those studies relied on ad hoc 
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and not comprehensive lists of chronic diseases. Second, the multimorbidity patterns were 
developed according to data-driven—not clinical—principles. Third, the dynamic and evolving 
nature of multimorbidity and other measures was not considered.   
1.3.6 Knowledge gaps antecedent to this thesis 
Despite many studies showing an independent impact of multimorbidity on several negative 
outcomes, some failed to demonstrate an independent association. On the one hand, this may 
be attributed to methodological inconsistencies in the way multimorbidity was operationalized. 
On the other hand, the scarce specificity implicit in the definition of multimorbidity—the co-
occurrence of two or more diseases—may lead to heterogeneous and unexpected results. In 
this regard, reducing the heterogeneity of the exposure and assessing more homogeneous 
clusters of multimorbidity can help to identify groups of chronic disease selectively associated 
with specific outcomes.   
Finally, several studies clearly showed that many older individuals are able to live a satisfying 
life in spite of the presence of multiple chronic diseases. Rather, the concurrent development 
of functional impairment is widely believed to drive the negative consequences of 
multimorbidity. Notably, only a handful of studies investigated the interplay between 
multimorbidity and functional impairment, and none of them assessed the role played by 
specific multimorbidity clusters. Understanding the effect of the interplay between 
multimorbidity and functional impairment in older adults may improve the detection of groups 
of individuals with more intense health-care needs and poor prognoses, in line with the 
principles of patient-centered care.           
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2 AIMS 
2.1 OVERALL AIM 
The overall aim of the present thesis was to propose a clinically driven methodology to assess 
multimorbidity in older individuals, to describe multimorbidity evolution over time, and to 
investigate the impact that cardiovascular and neuropsychiatric clusters of multimorbidity exert 
on older individuals’ health.  
2.2 SPECIFIC AIMS 
The specific aims addressed in four individual studies are summarized below. 
1. To propose a novel clinically driven approach for assessing and measuring 
multimorbidity, and to examine its applicability in a population-based cohort of older 
adults. 
 
2. To identify multimorbidity clusters in a population-based cohort of older adults, trace 
the evolution of the clusters over 12 years, and follow the clinical trajectories of the 
individuals as they moved between clusters or to death over time. 
 
3. To examine if multimorbidity clusters, defined by the copresence of cardiovascular and 
neuropsychiatric conditions, have a differential influence on the longitudinal evolution 
of function in older individuals. 
 
4. To explore the effect of cardiovascular multimorbidity and functional impairment, as 
well as the effect of neuropsychiatric multimorbidity and functional impairment, on all-
cause and cause-specific mortality. 
 
 
 
 
 
 
 
 
 
 
 
 17 
2 AIMS 
2.1 OVERALL AIM 
The overall aim of the present thesis was to propose a clinically driven methodology to assess 
multimorbidity in older individuals, to describe multimorbidity evolution over time, and to 
investigate the impact that cardiovascular and neuropsychiatric clusters of multimorbidity exert 
on older individuals’ health.  
2.2 SPECIFIC AIMS 
The specific aims addressed in four individual studies are summarized below. 
1. To propose a novel clinically driven approach for assessing and measuring 
multimorbidity, and to examine its applicability in a population-based cohort of older 
adults. 
 
2. To identify multimorbidity clusters in a population-based cohort of older adults, trace 
the evolution of the clusters over 12 years, and follow the clinical trajectories of the 
individuals as they moved between clusters or to death over time. 
 
3. To examine if multimorbidity clusters, defined by the copresence of cardiovascular and 
neuropsychiatric conditions, have a differential influence on the longitudinal evolution 
of function in older individuals. 
 
4. To explore the effect of cardiovascular multimorbidity and functional impairment, as 
well as the effect of neuropsychiatric multimorbidity and functional impairment, on all-
cause and cause-specific mortality. 
 
 
 
 
 
 
 
 
 
 
33
  18 
 
3 MATERIAL AND METHODS 
3.1 STUDY POPULATION 
3.1.1 The SNAC-K study 
This thesis is based on data from the Swedish National study on Aging and Care in 
Kungsholmen (SNAC-K) (133), which is an ongoing longitudinal population-based study of 
individuals aged 60 years or older residing at home or in an institution in the Kungsholmen 
area of Stockholm, Sweden. A random sample stratified across 11 birth cohorts born between 
1892 and 1939 was invited to participate (figure 5). Those accepting (N = 3,363; participation 
rate 73%), were examined for the first time in 2001–2004. Individuals from the oldest as well 
as the youngest birth cohorts were oversampled. Participants who were <78 years at baseline 
were followed up every 6 years and participants ≥78 years every 3 years.  
 
 
 
3.1.2 Study designs and selection criteria 
With the exception of Study I, which has a cross-sectional design, all the other studies included 
in the present thesis have a longitudinal design. A literature review and a consensus of experts 
were also part of Study I. Four different study samples were selected from the SNAC–K 
population in order to answer the research questions (that is, Studies I–IV). In Study I, 
information on the entire SNAC-K population was used (N = 3,363). In Study II, only 
participants that had two or more diseases at baseline were included (n = 2,931). In Study III, 
only participants with at least two valid assessments over a period of nine years were included 
Figure 5. SNAC-K cohorts (2001–2016). Grey boxes indicate baseline assessment, red boxes 1st 
follow-up, light-blue boxes 2nd follow-up, orange boxes 3rd follow-up and green boxes 4th follow-up. 
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in the analyses (n = 2,385). Finally, in Study IV, only participants with baseline valid 
information on walking speed and chronic disease were selected (n = 3,241).    
3.1.3 Data collection 
Data collection included information on participants’ current status and past history. 
Information was collected through interviews, clinical examinations, and specific tests. Staff 
components (nurses, psychologists, and physicians) received ad hoc training aimed at 
standardizing any procedure. At each wave, each individual was examined for an average of 
six hours. The examination included a biographic assessment and a measurement of physical 
functioning by a nurse (two hours); clinical examination by a physician for the geriatric, 
neurological, and psychological assessment (two hours); and cognitive evaluation by a 
psychologist (two hours). 
3.2 DISEASE ASSESSMENT 
3.2.1 Information source and collection 
In SNAC-K, clinical diagnoses were made on the basis of participants’ self-reported 
information, review of medical journals, anamnestic data, and information obtained from 
participants’ proxies. Further clinical and lab parameters, and information related to medication 
utilization, complemented physicians’ assessments of specific diseases. All drugs used by 
SNAC-K participants were noted and coded based on the Anatomical Therapeutic Chemical 
(ATC) classification. Participants were asked to provide a list of currently used medications. 
For participants with cognitive impairment, a proxy was asked instead. For participants living 
in a nursing home, medical records were consulted to gather information on medication 
utilization. All diseases were coded in accordance with the International Classification of 
Diseases 10th revision (ICD-10). 
For the studies included in this thesis, the Swedish National Patient Register (NPR) was also 
consulted for five years preceding the baseline and twelve years following the baseline. All in-
patient visits in Sweden since 1987 have been recorded in the. Starting in 2001, specialized 
outpatient visits, including day surgery and psychiatric care from both private and public 
providers, have been reported to the NPR. Once informed consent was obtained from the 
participants, the SKAC-K data were linked with the NPR through personal identification 
numbers. The ICD-10 codes used for identifying chronic diseases were based either on the 
primary diagnosis or on any of the nine secondary diagnoses recorded in the NPR.  
3.2.2 Disease categorization 
Building a clinically driven list of chronic diseases for the operationalization of multimorbidity 
was the main purpose of Study I. Five geriatricians and two general practitioners from Sweden, 
Italy, and Spain were involved in this process. The first step consisted of the classification as 
chronic or nonchronic of all ICD-10 codes, in accordance with a definition of chronic disease 
agreed on by the authors of the study. The second step consisted of classifying the identified 
chronic diseases into broader categories. For this, the following principles were considered: 
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pathophysiology, pharmacological and nonpharmacological treatment, prognosis, and 
prevalence. While we aimed to preserve the original structure of the ICD-10 codes, some 
modifications were made. First, some disorders, given their high prevalence or in light of their 
highly specific clinical characteristics, management, and prognosis, were isolated from the rest 
of the nosographic group, thereby becoming a separate disease category (e.g., diabetes 
[separate from metabolic], multiple sclerosis [separate from autoimmune], or inflammatory 
bowel disease [separate from colitis-related diseases]). Second, a series of diseases were 
removed from the original category and placed into a different nosographic group in light of 
their greater clinical homogeneity with the new group (e.g., chronic viral hepatitis was removed 
from “Chronic infectious diseases” and aggregated with “Chronic liver diseases”). Third, new 
disease categories were generated aggregating a range of infrequent codes involving common 
body organ/system pathophysiology (e.g., “Ear, nose and mouth disorders” or “Other 
neurological conditions”). Finally, some disease codes were placed in multiple categories when 
their labels specified multiple disease entities. (Spondylosis with myelopathy was included, for 
example, once in the group “Dorsopathies” and another time in the group “Other neurological 
disorders.”) As reported in the results section, this procedure led to the composition of 60 
homogeneous categories of chronic disease. 
3.2.3 Cardiovascular and neuropsychiatric diseases 
In Study I and Study II, all 60 disease categories were considered for the analyses. Conversely, 
Study III and Study IV focused on the prognostic role of cardiovascular and neuropsychiatric 
disease. Overall, seven chronic cardiovascular-disease groups were considered: atrial 
fibrillation, bradycardias and conduction disease, cardiac valve disease, heart failure, ischemic 
heart disease, peripheral vascular disease, and other cardiovascular disease. Similarly, twelve 
chronic neuropsychiatric disease groups were of interest: cerebrovascular diseases; dementia; 
depression and mood diseases; epilepsy; migraine and facial pain syndromes; multiple 
sclerosis; neurotic, stress-related and somatoform diseases; Parkinson and parkinsonisms; 
peripheral neuropathy; schizophrenia and delusional diseases; other neurological diseases; and 
other psychiatric diseases.  
With the aim of exploring the associations of specific disease patterns on trajectories of 
physical function, Study III participants were grouped based on the baseline number of 
cardiovascular and neuropsychiatric diseases (i.e., zero, one, or two or more). This 
categorization resulted in seven mutually exclusive groups (figure 6) that allowed us to 
investigate the impact on trajectories of function of (a) cardiovascular morbidity and 
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multimorbidity (two or more cardiovascular diseases plus two or more neuropsychiatric 
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In Study IV, in order to investigate the interplay between chronic disease and functional status, 
participants were categorized into six mutually exclusive groups derived from the combination 
of the number of cardiovascular and neuropsychiatric diseases (zero, one, or two or more) with 
the presence of slow walking speed (see definition below). 
3.3 FUNCTIONAL ASSESSMENT 
3.3.1 Walking speed 
In Study III and Study IV, walking speed was used as an indicator of physical function, as an 
outcome, and as an effect modifier, respectively. Walking speed was assessed by asking 
SNAC-K participants to walk 6.0 meters at their usual speed or, if not feasible (if participants 
had limited walking capacity to begin with or space was limited, for instance, in an institution), 
to walk 2.4 meters instead. Walking speed was measured in meters per second (m/s). In 
Study IV, a cutoff of 0.8 m/s was used to define slow walking speed in main analyses and 
1.0 m/s in sensitivity analyses.  
3.3.2 Independency 
In Study III, independency was assessed by the ability to independently perform the following 
six B-ADL: bathing, dressing, toileting, continence, transferring from bed, and eating. The B-
ADL score was obtained by summing the number of intact items; change over 9 years was 
considered one of the outcomes of the study.  
Figure 6. Participants’ categorization applied in Study III, based on the presence of zero, one, or 
two or more cardiovascular (CV) and neuropsychiatric (NP) diseases.  
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3.4 MORTALITY DATA 
All-cause mortality at three and five years was the main outcome in Study IV. In a secondary 
analysis, we examined cardiovascular causes of mortality (ICD-10 I00-I79) and 
noncardiovascular causes of mortality separately to explore whether specific clinical profiles 
were selectively associated with fatal cardiovascular events. To this end, only the underlying 
cause of death—and no secondary causes—was considered. Dates and causes of death were 
derived from death certificates provided by Statistics Sweden, the Swedish national statistics 
agency. 
3.5 COVARIATES 
Information on age, sex, education, and living arrangement was gathered by questionnaire. Age 
was used as a continuous variable for model adjustment and categorized as <75 and ≥75 years 
for stratifying analyses. Education was measured as the total years of formal schooling and 
categorized as elementary (<8 years), high school (8–13 years), and university or higher 
(>13 years). Living arrangement was categorized as living in institution or not. In keeping with 
the recommendations of the European Society for Clinical Nutrition and Metabolism (ESPEN), 
malnutrition was defined as having a body mass index (BMI) <18.5 kg/m2 (134). The number 
of drugs used at the moment of the assessment was obtained by summing up retrieved ATC 
codes. Global cognition was assessed through the 30-item Swedish version of the Mini-Mental 
State Examination (MMSE). MMSE is a questionnaire covering cognitive functions such as 
orientation to time and space, attention and calculation recall, language, ability to follow 
written and verbal commands, and visual construction (135). 
3.6 STATISTICAL ANALYSES  
In the four studies included in the present thesis, participants’ characteristics were reported as 
absolute numbers and proportion (%), or mean ± standard deviation (SD), or 95% confidence 
intervals (95% CI), as appropriate. A P value of <0.05 was considered statistically significant 
in all analyses. All analyses were carried out with Stata® 14.0 and Stata 15.0 (StataCorp LP) 
for Microsoft Windows®, and with R 3.5.1. Specific analytical strategies were adopted in each 
of the four studies (summary in table 1). 
3.6.1 Study I 
Age- and sex-specific weights were applied to chronic-disease prevalence figures in order to 
account for the SNAC-K sampling method. In order to verify if categorization into 
60 homogeneous groups of chronic disease led to an underestimation of specific conditions, 
and consequently multimorbidity, we calculated the number of people with two or more 
differing ICD-10 codes within the same disease category.  
3.6.2 Study II 
Clusters of older adults who shared patterns of multimorbidity were independently identified 
using the fuzzy c-means cluster analysis at baseline, six, and twelve years. Through this 
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technique, we obtained clusters of individuals and a membership matrix that indicated the 
degree of participation of each individual in each cluster. Different degrees of fuzzification and 
several validation indices were considered to estimate the optimal number of clusters. We based 
our evaluation of the consistency and significance of the final solution on clinical criteria. To 
characterize the clusters of multimorbidity that corresponded to each cluster of individuals, we 
calculated the frequency of chronic diseases in each cluster. Observed-to-expected (O/E) ratios 
were calculated by dividing the prevalence of a given disease within a cluster by its prevalence 
in the overall population. Disease exclusivity, defined as the fraction of participants with the 
disease in the cluster over the total number of participants with the disease, was also calculated. 
We considered a disease to be associated with a given cluster of individuals when the O/E ratio 
was ≥2 or the exclusivity was ≥25%. To evaluate the most likely clinical trajectories of the 
participants as they moved between clusters over time, a hard cut of fuzzy c-means assigned 
each individual to the cluster with the highest membership score at each time point (136, 137). 
Shifts between clusters were computed by cross-tabulating individuals between each wave 
(baseline to six-year follow-up and six- to twelve-year follow-up). Frequencies (%) of 
participants who changed from one cluster to another were computed to assess the overlap 
between waves. Mortality and dropout status were considered as fixed clusters in both six- and 
twelve-year follow-ups. Logistic regression models were used to estimate the association 
between clusters and mortality. Odd ratios (OR) and 95% CI were adjusted for age, sex, and 
education. All comparisons were adjusted for multiplicity. 
3.6.3 Study III 
Mixed-effect linear regression models were used to draw trajectories of walking speed and B-
ADL over nine years across seven different combinations of cardiovascular and 
neuropsychiatric disease. Participants without cardiovascular and neuropsychiatric disease 
served as reference. Follow-up time was modelled through unrestricted cubic splines. In a 
second analysis, the association between the seven disease combinations and the outcomes was 
tested in mixed-effect linear regressions including both the exposure and the adjustment 
variables (i.e., number of prescribed drugs, malnutrition, and institutionalization) as time-
varying covariates. Interaction between clinical patterns on one side and sex and age on another 
was tested, and further stratified analyses were performed. A series of sensitivity analyses were 
carried out. First, we re-estimated all models, after excluding the most common cardiovascular 
and neuropsychiatric diseases one disease at a time from the total count of the respective 
multimorbidity clusters. Second, we repeated all analyses, using a subsample of known 
survivors, who neither died nor were lost to follow-up. Finally, we re-estimated all models, 
after removing incontinence from the list of B-ADL impairments. 
3.6.4 Study IV 
Three- and five-year mortality rates (per 100 person years) were provided for each clinical 
profile. Cox regressions were used to test the association between the clinical profiles built by 
combining baseline walking speed (<0.8 m/s and ≥0.8 m/s) and the number of cardiovascular 
or neuropsychiatric diseases and three- and five-year all-cause mortality. Participants with a 
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walking speed of ≥0.8 m/s and without cardiovascular or neuropsychiatric disease were the 
reference group. We tested multiplicative and additive (relative excess risk due to interaction, 
RERI) interactions between walking speed and cardiovascular and neuropsychiatric 
multimorbidity. Fine-Gray competing risk regression models were used to test the association 
between clinical profiles and cause-specific (cardiovascular and noncardiovascular) mortality. 
In a sensitivity analysis, the analyses were repeated, taking participants without cardiovascular 
or neuropsychiatric disease and a walking speed of <0.8 m/s as the reference group. In a second 
sensitivity analysis, a walking speed cutoff of <1 m/s was used. Finally, the association between 
the number of cardiovascular and neuropsychiatric diseases and mortality was tested in Cox 
regression models, adjusted and not for walking speed, as a continuous—instead of an 
indicator—variable. For these models, the Harrell’s C statistic was obtained. Finally, the 
predicted values of the hazards of mortality were plotted against walking speed as a continuous 
variable (with a walking speed of 0.8 m/s as reference). 
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3.7 ETHICAL CONSIDERATIONS 
This dissertation was based on data collected in the SNAC-K study. All SNAC-K phases and 
the use of Patient Register data were approved by the Ethics Committee at Karolinska Institutet, 
Stockholm, Sweden, and the Regional Ethical Review Board in Stockholm (Dnrs: KI 01-114, 
04-929/3, Ö26-2007, 2009/595-32, 2010/447-31/2, 2013/828-31/3, and 2016/730-31/1). 
Written informed consent was obtained from all SNAC-K participants. For individuals with 
cognitive impairment at baseline or during follow-up visits, consent was obtained from the next 
of kin (family members or caregivers). 
Study participants were assessed in a friendly and comfortable environment. Each test and 
examination was performed in accordance with the participants’ willingness to undergo the 
procedure. Every time the assessors perceived some kind of distress for the participants, the 
test was stopped and eventually rescheduled. The same applied to blood test sampling: the 
minimum necessary blood amount was sampled, and participants could refuse consent to the 
procedure. Subjects were asked if they wanted to be informed of any condition detected during 
the examination. If any test results were abnormal, participants were referred to their general 
practitioner or emergency room, if necessary. Finally, the main results of research conducted 
on SNAC-K data were disseminated to participants through annual seminars held by the 
researchers, booklets of scientific results, and popular science publications.  
All collected data were anonymized once they were digitalized from the questionnaires. An 
artificial ID was given to each participant and all personal data removed. All researchers 
working with the data set respected and followed the ethical guidelines of the Swedish Council 
for Research in the Humanities and Social Sciences. 
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4 RESULTS 
4.1 CHARACTERISTICS OF THE STUDY POPULATION  
At baseline, the mean age of the 3,363 participants in SNAC-K was 74.6 ± 11.2, 64.9% were 
female, and 5.7% lived in an institution. Over nine years of observation, 38.7% participants 
died, and 15.2% dropped out. Dropouts occurred when the participant or her or his relative 
refused, contact with the participant was lost, or the participant moved from the Stockholm 
area. As previously mentioned, specific inclusion criteria were applied to Study II, Study III, 
and Study IV; sample characteristics are reported in the corresponding articles. 
4.2 CHRONIC DISEASE DEFINITION AND CATEGORIZATION (STUDY I)  
Based on expert consensus, a disease was considered chronic if it had a prolonged duration and 
either (a) left residual disability or worsening quality of life, or (b) required a long period of 
care, treatment, or rehabilitation. After revising all the ICD-10 codes, 918 were classified as 
chronic and further categorized into 60 homogeneous groups (table 2). Of all 3,363 SNAC-K 
participants and 60 disease groups, 13 participants showed a prevalence >10%, 35 had a 
prevalence between 1% and 10%, and 12 <1%. Overall, only 3.2% of the participants had zero 
diseases, 8.2% had one disease, 88.6% had two or more diseases, and 73.2% had three or more 
diseases. For both males and females, the number of chronic diseases increased with age (figure 
7). The three most frequent diseases were hypertension (69%), dyslipidemia (46%), and 
chronic kidney disease (38%). Finally, we found that the proportion of people with two or more 
different ICD-10 codes within a given disease category was <1% of all participants in that 
category.  
 
 
 
 
 
 
Figure 7. Percent distribution of chronic disease categories by age and sex in the Swedish National 
Study on Aging and Care in Kungsholmen (SNAC-K; N = 3363). Data source: Journals of 
Gerontology: Medical Sciences 2017 (1). 
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4.3 TRAJECTORIES OF CLUSTERS OF MULTIMORBIDITY (STUDY II) 
In the analytical sample of Study II, including 2,931 individuals with two or more diseases at 
baseline, the mean age was 76.1 ± 11.0, and 66.6% were females. Five clusters of people were 
identified at baseline: those with psychiatric and respiratory disease (5.4%), heart disease 
(9.3%), respiratory and musculoskeletal disease (15.7%), cognitive and sensory impairment 
(10.6%), and eye disease and cancer (10.7%). However, half of the people (48.7%) were 
grouped in an unspecified group, as they were affected by prevalent diseases of which the 
occurrence did not exceed the expected. At baseline, demographic, clinical, and functional 
characteristics were differentially distributed across the clusters.  
Participants in the cognitive and sensory disease, the eye disease and cancer, and the heart 
disease clusters were the oldest. Participants in the heart disease, the eye disease and cancer, 
and the psychiatric and respiratory disease clusters presented the greatest number of chronic 
diseases. Participants in the heart disease and psychiatric and respiratory disease clusters and 
those in the cognitive and sensory impairment cluster used the highest number of drugs. 
Moreover, individuals included in the heart disease, the eye disease and cancer, and the 
cognitive and sensory impairment clusters presented the highest prevalence of disability and 
slow walking speed. Those clusters, together with the psychiatric and respiratory disease 
cluster, showed the lowest MMSE scores. The unspecified group of participants was 
characterized by the lowest mean age, the lowest number of chronic disease and drugs, and 
better functional status. Yet it had a high prevalence of hypertension, diabetes, dyslipidemia, 
and obesity.  
Five clusters were identified at six and twelve years. At follow-ups, those diseases 
characterizing the baseline clusters were regrouped into different multimorbidity clusters. In 
spite of varied clustering, a similar clinical distribution was observed for the different types of 
disorders. Figure 8 depicts the longitudinal evolution of multimorbidity clusters over twelve 
years and includes both the change over time of disease patterns (the diseases that characterize 
a specific cluster of individuals) and the migration of participants from one cluster to another.  
Over the twelve years, 1,290 (44%) deaths occurred. At baseline the heart disease, the cognitive 
and sensory impairment, and the psychiatric and respiratory disease clusters were significantly 
associated with the highest six-year mortality compared with the people who were not part of 
any cluster. These clusters accounted for 51% of deaths. At first follow-up, the heart and 
vascular disease, the heart disease, and neuropsychiatric and respiratory disease clusters had 
the highest OR for six-year mortality when compared with the unspecified group. These 
clusters accounted for 57% of deaths in the following six years. 
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4.4  CARDIOVASCULAR AND NEUROPSYCHIATRIC MULTIMORBIDITY AND 
PHYSICAL FUNCTION (STUDY III) 
In the analytical sample of Study III, including at baseline 2,385 participants with at least two 
valid assessments over nine years, the mean age was 72.9 ± 10.3 years, and 65% were females. 
Figure 9 depicts the distribution in the study sample of the chronic disease patterns based on 
the number of cardiovascular and neuropsychiatric diseases. 
     
 
Figure 10 shows the trajectories of walking speed and B-ADL score predicted for the disease-
load clusters over nine years of follow-up. Irrespective of the presence or not of cardiovascular 
diseases, those with several neuropsychiatric diseases experienced the most drastic drop in 
walking speed as well in the number of preserved B-ADL. Individuals with cardiovascular 
multimorbidity experienced steeper deterioration in walking speed over time, relative to those 
in the reference group, although such effect was not present for disability trajectories. 
Individuals with a copresence of multiple cardiovascular and neuropsychiatric conditions 
experienced the largest drop in walking speed (up to 0.7 m/s; p <0.001) and B-ADL (up to 3 B-
ADL, p <0.001) over nine years, relative to the control group. 
In additional analyses, in which both disease patterns (exposures) and adjustment variables 
were considered as time-varying covariates, the negative association between walking speed 
and having just one cardiovascular disease became only marginally statistically significant (β 
= −0.03; 95% confidence interval [CI] −0.07 to 0.00). Importantly, all other clinical patterns 
preserved their negative statistically significant association with walking speed, with the 
strongest one being that involving neuropsychiatric multimorbidity (β = −0.20; 95% CI −0.24 
to −0.16) and complex multimorbidity (β = −0.21; 95% CI −0.25 to −0.18). Regarding the 
disability trajectories, all patterns involving at least one neuropsychiatric condition 
(characterizing 25% of the study population) were associated with a faster decline in B-ADL, 
Figure 9. Participant categorization used in Study III, based on the presence of zero, one, or two or 
more cardiovascular (CV) and neuropsychiatric (NP) diseases. 
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and mixed multimorbidity and complex multimorbidity exhibited the largest association 
estimates (β = −0.20; 95% CI −0.30 to −0.11; β = −0.27; 95% CI −0.34 to −0.19, respectively). 
Generally, functioning was reduced between 5% and 20% in those with the most complex 
clinical patterns, relative to the reference group. Older age and female sex generally 
exacerbated the negative association between the clinical patterns and disability and walking 
speed. The pattern of the associations remained intact after excluding individuals with the most 
prevalent cardiovascular and neuropsychiatric diseases.   
 
 
 
 
Figure 10. Trajectories of walking speed and ADL impairment over nine years by clinical patterns. 
Trajectories derived from mixed-effect linear regressions adjusted for baseline age, sex, education, 
malnutrition, institutionalization, and number of medications. Reference group: participants free 
from cardiovascular and/or neuropsychiatric diseases. CV = cardiovascular; NP = neuropsychiatric. 
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4.5 PROGNOSTIC ROLE OF WALKING SPEED (STUDY IV) 
In the analytical sample of Study IV, including 3,241 participants with valid baseline 
measurements of walking speed, the mean age was 74.3 ± 11.0 years, and 64.4% were females. 
One third of baseline participants reported a walking speed of <0.8 m/s. By the three-year 
follow-up, 411 participants (12%) were deceased: 174 (5%) from cardiovascular causes and 
237 (7%) from other causes. A further 682 (21%) individuals died by the time of the five-year 
follow-up: 287 (9%) of cardiovascular and 395 (12%) of other causes. According to the 
findings in table 3, a greater cardiovascular burden was associated with an elevated three-year 
mortality risk only in the presence of slow walking speed (reference group: preserved walking 
speed and no cardiovascular disease). The pattern of results was similar for five-year mortality, 
although this time, even in the presence of preserved walking speed, having one or two 
cardiovascular conditions was associated with greater risk of death. An increasing burden of 
neuropsychiatric disease was associated with greater three-year mortality among individuals 
with slow walking speed, relative to participants with intact walking speed and no 
neuropsychiatric disease (table 3). When looking only at individuals with slow walking speeds, 
the crude excess risk of three-year mortality was 18.4/100 person-years in those with two or 
more cardiovascular diseases and 17/100 in those with two or more neuropsychiatric diseases 
(reference: intact walking speed). While some minor attenuation of results was observed for 
the five-year follow-up, the pattern remained consistent. Quantifying the joint effect of 
multimorbidity and walking speed on mortality using additive interaction revealed that 42% 
and 34% of the relative excess risk of death was attributable to the effect of slow walking speed 
and cardiovascular and neuropsychiatric multimorbidity, respectively.  
Table 3. Association between cardiovascular and neuropsychiatric multimorbidity by walking speed. 
 
 
WS = walking speed; IR = incident rate; HR = hazard ratio; CI = confidence interval 
 
 33 
4.5 PROGNOSTIC ROLE OF WALKING SPEED (STUDY IV) 
In the analytical sample of Study IV, including 3,241 participants with valid baseline 
measurements of walking speed, the mean age was 74.3 ± 11.0 years, and 64.4% were females. 
One third of baseline participants reported a walking speed of <0.8 m/s. By the three-year 
follow-up, 411 participants (12%) were deceased: 174 (5%) from cardiovascular causes and 
237 (7%) from other causes. A further 682 (21%) individuals died by the time of the five-year 
follow-up: 287 (9%) of cardiovascular and 395 (12%) of other causes. According to the 
findings in table 3, a greater cardiovascular burden was associated with an elevated three-year 
mortality risk only in the presence of slow walking speed (reference group: preserved walking 
speed and no cardiovascular disease). The pattern of results was similar for five-year mortality, 
although this time, even in the presence of preserved walking speed, having one or two 
cardiovascular conditions was associated with greater risk of death. An increasing burden of 
neuropsychiatric disease was associated with greater three-year mortality among individuals 
with slow walking speed, relative to participants with intact walking speed and no 
neuropsychiatric disease (table 3). When looking only at individuals with slow walking speeds, 
the crude excess risk of three-year mortality was 18.4/100 person-years in those with two or 
more cardiovascular diseases and 17/100 in those with two or more neuropsychiatric diseases 
(reference: intact walking speed). While some minor attenuation of results was observed for 
the five-year follow-up, the pattern remained consistent. Quantifying the joint effect of 
multimorbidity and walking speed on mortality using additive interaction revealed that 42% 
and 34% of the relative excess risk of death was attributable to the effect of slow walking speed 
and cardiovascular and neuropsychiatric multimorbidity, respectively.  
Table 3. Association between cardiovascular and neuropsychiatric multimorbidity by walking speed. 
 
 
WS = walking speed; IR = incident rate; HR = hazard ratio; CI = confidence interval 
49
  34 
Figure 1 shows the hazard ratios (HRs) for three-year all-cause mortality across walking speed 
(continuous variable), depending on the number of cardiovascular and neuropsychiatric 
diseases. Participants with a speed of <0.8 m/s had a higher mortality (dashed line). Mortality 
was exacerbated in the presence of one or more cardiovascular or neuropsychiatric diseases. 
Individuals with two or more neuropsychiatric diseases did not differ in mortality risk from 
those with one neuropsychiatric disease. The pattern of results was unchanged at five years. 
Focusing exclusively on individuals who died of cardiovascular causes, cardiovascular diseases 
were associated with a greater relative risk of three-year mortality, irrespective of walking 
speed. Examining those who died of causes other than cardiovascular disease revealed that a 
higher burden of cardiovascular diseases was associated with a greater change in three-year 
mortality only in individuals with slow walking speeds. These findings remained consistent 
after a five-year mortality follow-up, as well as in the analysis of neuropsychiatric conditions. 
An alternative cutoff of <1 m/s to define slow walking speed did not affect the pattern of the 
associations presented.     
 
 
 
Figure 11. Estimated hazard ratio (HRs) of 3-year all-cause mortality for different values of walking 
speed (reference 0.8 m/s) in the overall population (centering the number of diseases on their average 
number) and in participants with 0, 1, or 2+ cardiovascular and neuropsychiatric diseases. 
 
Cox regression models adjusted for age, sex, education, number of NP diseases or CV diseases, number 
of medications, malnutrition, institutionalization, and Mini-Mental State Examination score. 
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were associated with a greater relative risk of three-year mortality, irrespective of walking 
speed. Examining those who died of causes other than cardiovascular disease revealed that a 
higher burden of cardiovascular diseases was associated with a greater change in three-year 
mortality only in individuals with slow walking speeds. These findings remained consistent 
after a five-year mortality follow-up, as well as in the analysis of neuropsychiatric conditions. 
An alternative cutoff of <1 m/s to define slow walking speed did not affect the pattern of the 
associations presented.     
 
 
 
Figure 11. Estimated hazard ratio (HRs) of 3-year all-cause mortality for different values of walking 
speed (reference 0.8 m/s) in the overall population (centering the number of diseases on their average 
number) and in participants with 0, 1, or 2+ cardiovascular and neuropsychiatric diseases. 
 
Cox regression models adjusted for age, sex, education, number of NP diseases or CV diseases, number 
of medications, malnutrition, institutionalization, and Mini-Mental State Examination score. 
50
  35 
5 DISCUSSION 
5.1 MAIN FINDINGS 
In this doctoral thesis, a methodology was proposed to assess and measure multimorbidity in 
older individuals, describe the longitudinal evolution and prognosis of multimorbidity clusters, 
and investigate the extent to which clusters of cardiovascular and neuropsychiatric 
multimorbidity impact and interact with physical function.  
The main findings of the project can be summarized as follows.  
1. When applying a comprehensive and clinically driven methodology to its assessment, 
multimorbidity—the presence of two or more diseases in a single person—is present in 
nine out of ten individuals aged 60 years and older (Study I).  
 
2. Clinical trajectories of older adults with multimorbidity are characterized by great 
dynamism and complexity but can still be tracked over time. Over 12 years, changes in 
cluster composition, participants’ transitions from one cluster to another, and 
participant mortality generated a dynamic but well-defined clinical picture (Study II).  
 
3. Different combinations of cardiovascular and neuropsychiatric disease exert a 
differential impact on independence and walking speed in older adults, with 
neuropsychiatric diseases (alone or combined with others) showing the strongest 
association with functional decline (Study III).  
 
4. In older adults, the assessment of walking speed provides further prognostic 
information to the association of cardiovascular morbidity with mortality, and 
neuropsychiatric morbidity with mortality (Study IV). 
 
5.2 ASSESSING CHRONIC DISEASES AND MULTIMORBIDITY IN OLDER 
ADULTS 
As previously stated, despite general agreement on multimorbidity defined as the concurrent 
presence of two or more diseases, and as the most frequent chronic condition encountered in 
older people, less unanimity characterizes studies reporting the prevalence of multimorbidity 
in the older population (55% to 98%) (27). The greater part of such discordance is driven by 
methodological pitfalls related to the way multimorbidity is assessed (1, 52). In fact, the lack 
of a standard and clinically driven list of chronic diseases, both for clinical and research 
purposes, has led several authors to rely on discretional criteria (52). The first inconsistencies 
that emerged from the literature concerned the inclusion of both chronic and acute conditions 
(e.g., pulmonary embolism) in the measurement of multimorbidity, as well as the different 
weight given to some of the aspects defining a chronic disease (e.g., duration, treatment). In 
this regard, the first output of Study I was to reach consensus on the definition of what in older 
people can be reliably considered a chronic disease—namely a condition that has a prolonged 
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duration and, either (a) leaves residual disability or worsening quality of life, or (b) requires a 
long period of care, treatment, or rehabilitation. With this definition, 918 ICD-10 codes could 
be classified as chronic. Another issue was the varying number of conditions assessed in 
previous studies, ranging from a few to more than hundred diseases (1, 52). This mainly 
depended on the level of aggregation of nosological entities included by other authors. For 
example, sometimes atrial fibrillation is counted as an individual condition, while in other cases 
atrial fibrillation is included in the wider category of heart disease. In Study I, after selecting 
918 chronic ICD-10 codes, we reduced them to 60 homogeneous categories of chronic disease, 
taking into account pathophysiologic, treatment-related, prognostic, and prevalence criteria. 
The result, upon applying this list of chronic conditions, was that 88.6% of SNAC-K 
participants were affected by chronic multimorbidity. Such prevalence is among the highest 
reported in the literature (27). Two main reasons may explain this finding. First, this is one of 
the most comprehensive lists of chronic disease provided so far. Beyond the most prevalent 
diseases, a number of conditions were included that were characterized by a low prevalence, 
even in older adults. Note that 12 out of 60 diseases had a prevalence <1% within the SNAC-
K population. Those conditions, such as epilepsy, inflammatory bowel disease, and chronic 
liver disease, despite being rare, exert an undeniable negative burden on older individuals’ 
health and survival. Second, in SNAC-K, the detection of chronic disease is based on a 
comprehensive clinical and instrumental assessment carried out by physicians, nurses, and 
psychologists, minimizing the underdetection of several conditions. Moreover, the linkage of 
the SNAC-K database with the Swedish National Patient Register further improves disease 
detection.             
5.3 QUESTIONING THE “TWO OR MORE” CONCEPT 
That 9 in 10 older individuals have two or more diseases (Study I) when a thorough assessment 
is performed makes it a threshold of uncertain relevance (52). In fact, based on the given 
definition of multimorbidity, physicians would consider it to “affect” almost 100% of their 
older patients, epidemiologists would struggle to see multimorbidity as a valuable prognostic 
tool, and public health experts would find it hard to identify 9 in 10 as a population at risk. It is 
not surprising that the studies that defined multimorbidity as a mere dichotomous metric failed 
to demonstrate an association with several health-related outcomes, especially when function 
and disability have been taken into consideration (12). That such a threshold is applied to a 
disease count, independently of the type of disease encountered, further weakens the construct. 
Indeed, many would agree that a person with dementia plus heart failure should have a 
completely different prognosis than a person with allergy plus prostate hypertrophy—despite 
both being affected by multimorbidity.  
Two different ways of operationalizing the concept of multimorbidity have emerged in recent 
years. The first is the concept of associative multimorbidity, based on the observation that 
chronic diseases cluster within the same individual according to specific patterns reflecting 
their pathophysiological commonalities (36). This approach has a strong clinical valence, given 
that similar risk factors, prognoses, and treatments may be identified across diseases belonging 
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to the same pattern (1, 51, 93). An alternative way to study the phenomenon of multimorbidity 
is through its development and progression over time, namely the speed of accumulation of 
chronic diseases in a single person. This approach is rooted in the gerontological significance 
of multimorbidity, establishing a close relationship between the speed of accumulation of 
diseases and the pace at which the aging process advances (85). Studies II, III and IV focused 
on the description of the occurrence and prognosis of multimorbidity clusters in older adults.  
5.4 THE DYNAMIC NATURE OF MULTIMORBIDITY CLUSTERS 
In Study II, using a flexible cluster analysis method, we described the occurrence and the 
evolution of multimorbidity clusters across 12 years in the SNAC-K population. The main 
advantages and the novelty of this study are represented by the use of a method that (a) 
identifies clusters of individuals, not diseases and (b) does not force participants to belong to a 
cluster but attributes them a probability of belonging to a cluster. The approaches previously 
used to study patterns of multimorbidity in older individuals include the estimation of O/E 
ratios and ORs of the most commonly coexisting couples or triads of chronic disease, as well 
as cluster and factor analysis (27). However, the limitations of these analytical strategies restrict 
their interpretation and clinical relevance. The need for large samples, the issue of multiple 
comparisons, and the forcing of diseases into single clusters according to similarity or 
dissimilarity measures represent some of these limitations. Another important limitation of 
previous studies is their cross-sectional design (51). Given that a dynamic evolution of 
multimorbidity clusters is expected over time, their assessment at a single time point may be 
reductionist and biased.  
According to our analytical approach, only half of the SNAC-K participants with two or more 
diseases could be grouped at baseline into one of five multimorbidity clusters. The rest were 
not sorted into any cluster and were characterized by having a younger age, lower numbers of 
co-occurring diseases and drugs, good functional and cognitive abilities, and a high percentage 
of cardiovascular risk factors. This unspecified group, despite not identifying any specific 
cluster at baseline, contributed to several clusters identified at the six-year follow-up with a 
proportion varying from 29% to 49%, and to the clusters identified at the twelve-year follow-
up with a proportion varying from 16% to 50%. The most relevant contribution was observed 
toward those clusters characterized by cardiovascular, eye, respiratory, and musculoskeletal 
diseases. This finding reflects the fact that cardiometabolic conditions such as diabetes, obesity, 
dyslipidemia, and hypertension are important risk factors for the development of several 
cardiovascular and noncardiovascular diseases (138). 
Over 12 years, the evolution of cluster composition, participants’ transitions from one cluster 
to another, and mortality generated dynamic but well-defined clinical paths. The first 
remarkable trajectory has been mentioned and involved the unspecified cluster that includes 
individuals at their first stage of the multimorbidity process. The second relevant trajectory was 
driven by the high mortality of individuals in clusters characterized by cardiovascular and 
neuropsychiatric disease, which, despite representing only 25%, 28%, and 29% of the 
participants at baseline, 6 years, and 12 years, respectively, accounted for 51% and 57% of 
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deaths during the first and second follow-up periods, respectively. In Study IV, the relationship 
between cardiovascular and neuropsychiatric multimorbidity was further investigated. A final 
group of trajectories from one cluster to another could have been driven by several 
mechanisms. For example, one disease may result from another. This may explain why a large 
number of people in the heart disease cluster at baseline became part of the heart disease and 
cognitive impairment cluster at 6 years. The association between heart disease and cognitive 
decline may be supported by different mechanisms such as emboli, ischemic events, small 
vessel disease, cerebral hypoperfusion, and hypoxia (62, 139). Another possible pathway is 
represented by iatrogenic events, as when a disease results from the pharmacological or surgical 
treatment of another condition. For example, an association that was part of the 
neuropsychiatric and respiratory disease cluster and remained over the entire course of study 
may be linked to the steroid treatment of respiratory diseases, which can cause neurotic 
symptoms and depression (140). Finally, overlapping symptomatology may result in diseases 
being misdiagnosed in an initial phase. This may be the case of some baseline psychiatric 
conditions in the psychiatric and respiratory diseases cluster, which at 6 or 12 years may have 
evolved into, or been correctly classified as, cognitive impairment and dementia, justifying the 
cognitive impairment, psychiatric, and respiratory disease cluster (141).      
Only a handful of studies addressed the issue of the longitudinal development of 
multimorbidity. The study with comparable methodology was carried out in Spain and found 
at baseline six multimorbidity clusters: musculoskeletal, endocrine-metabolic, 
digestive/respiratory, neuropsychiatric, cardiovascular, and an unspecified group. These 
clusters showed less variation over six years than those identified in Study II. The shorter 
follow-up and use solely of primary-care electronic records may contribute to the differences 
(53, 142). Beyond the abovementioned report, three others from the Netherlands, Denmark, 
and Australia investigated the longitudinal accrual of diseases, leading to results only partially 
concordant with the results of this thesis. Once again, sample selection, the lack of clinical 
assessment of disease, the use of electronic information, and different analytical approaches 
make comparison difficult (55, 56, 58). 
5.5 ASSOCIATION AND INTERPLAY BETWEEN CHRONIC DISEASE AND 
FUNCTION 
In this thesis, both the association between multimorbidity and functional decline and the 
interplay between the two have been investigated. Given the prevalence and burden of 
cardiovascular and neuropsychiatric conditions in the older population, and considering that 
such disease characterizes most of the multimorbidity clusters previously identified in the 
literature, the focus here is on these two disease groups (51). Findings from Study III show that 
multimorbidity patterns combining cardiovascular and neuropsychiatric diseases are 
differentially associated with walking speed and B-ADL decline in older individuals (93). The 
pattern that includes multiple cardiovascular and neuropsychiatric diseases is associated with 
the worst trajectory in both walking speed and B-ADL, compared with people without 
cardiovascular and neuropsychiatric disease, suggesting that the interplay among diseases 
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belonging to different body systems is stronger than diseases with similar pathophysiology that 
belong to the same group. This is in line with two studies from Quiñones et al. that describe 
how multimorbidity patterns including a combination of mental and somatic diseases are more 
often associated with the worst functional trajectories (131, 132). Interestingly, 
neuropsychiatric diseases, independently of cardiovascular diseases, are shown in this thesis to 
be the major determinants of functional decline. Isolated cardiovascular multimorbidity is only 
associated with changes in walking speed. This contrasts with a study by Jackson et al. 
including only women, in which both cardiovascular and neuropsychiatric multimorbidity were 
independently and significantly associated with a steeper development of disability (129). A 
number of characteristics differentiate this from previous studies, challenging any direct 
comparison. First, the assessment of chronic disease and multimorbidity is based on the 
comprehensive and clinically driven methodology proposed in Study I. Second, multimorbidity 
patterns are not defined by data-driven procedures, but rather considered from all 
cardiovascular and all neuropsychiatric conditions listed. Finally, this is the first study that 
includes time-varying information related to multimorbidity, thus including the dynamic nature 
of this condition, as shown in Study II.  
In Study IV, this knowledge is expanded by investigating the interplay of cardiovascular and 
neuropsychiatric multimorbidity with functional ability, in association with mortality. Walking 
speed was found to provide additional prognostic information on mortality at three and five 
years, beyond the number of both cardiovascular and neuropsychiatric diseases. For SNAC-K 
participants with a slow walking speed, the association with all-cause and cardiovascular 
mortality was stronger for cardiovascular diseases. While the number of cardiovascular 
diseases has a discriminative power for mortality in individuals walking at slow speed, the 
same strong differential association cannot be found for neuropsychiatric diseases. An 
explanation of this finding may be that, given the strong association between neuropsychiatric 
disease and functional decline observed in Study III, slow walking speed may act more as a 
mediator than an effect modifier, buffering the direct effect that neuropsychiatric diseases may 
exert on mortality (93). Such consideration remains to be tested in further longitudinal studies. 
No comparison with other studies is possible as, to the best of our knowledge, ours is the first 
addressing the relationship between walking speed and multimorbidity.     
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5.6 METHODOLOGICAL CONSIDERATIONS 
5.7 STUDY DESIGN 
For all the studies included in this thesis we used the population-based cohort of individuals 
participating in the SNAC-K study. A few exclusion criteria were applied at baseline: age <60 
years, nonproficiency in the Swedish language, and residency outside the Kungsholmen district 
in Stockholm. The final participants resulted in a healthier and wealthier group of individuals, 
compared not only to nonparticipants but also to the Swedish population.  
5.7.1 Random error 
Two types of random error from sample variance and measurement error are commonly 
observed in research.  
5.7.1.1 Sampling error 
The aim of sampling a population is to operate with a smaller number of observations while 
preserving the representativeness of the whole population. However, a certain level of 
discrepancy between the obtained estimates and the true ones can always be expected. 
Randomly sampling the population and increasing the sample size may help to address this 
variation and improve the precision of the estimates.  
5.7.1.2 Measurement random error 
Random error can be also attributed to measurements’ imprecision. For instance, in SNAC-K, 
walking speed is assessed only once at each study wave, increasing the likelihood of 
measurement error by either the assessor (not following the exact procedure) or the participant 
(not understanding the task). A way to control for this type of error is to collect multiple 
assessments per individual and average them. Nevertheless, gait speed has shown to be a fairly 
robust measure when assessed only once, despite a lack of repeated assessments (143). 
SNAC-K assessors are trained in clinical assessment and data collection, and standardized 
protocols are used, with the aim of reducing measurement errors. 
5.7.2 Systematic error (bias) 
Systematic errors are common issues in every study design as well. Any systematic error that 
arises in designing, conducting, or analyzing the study and results in an error in the estimate is 
defined as bias.  
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arises in designing, conducting, or analyzing the study and results in an error in the estimate is 
defined as bias.  
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5.7.2.1 Selection bias  
The first type of selection bias potentially encountered in the SNAC-K study is the one arising 
during baseline sample selection. Although based on random sampling, selection bias may arise 
because someone accepts to participate to the study and someone else does not. Out of 5,111 
people initially invited to participate to SNAC-K, 521 were not eligible (200 died, 262 had no 
contact information, and 59 were deaf, moved away, or were not Swedish speakers). Out of the 
remaining 4,590, 1,227 declined to participate, leaving a study population of 3,363 people 
(participation rate 73%). Participation rates were above 70% in all age groups and were similar 
among males and females. On the one hand, decliners may be older, less educated, affected by 
more chronic diseases, or disabled, all characteristics that could prevent them from 
participating in the study. In our studies, this could have led to an underestimation of the 
association between exposure and outcome. On the other hand, decliners may be younger, be 
still working, and not have time to be part of the study. This latter scenario could have led to 
an overestimation of the association. The proportion of people living in institutions was 
significantly higher among participants (6%) than among nonparticipants (<1%). For age 
cohorts 60 through 87, shorter time to death after the beginning of the study was associated 
with a higher likelihood of nonparticipation. Nonparticipants were also older. Thus, in our 
project the first scenario is more likely to have occurred.  
Another type of selection bias of study participants arises from longitudinal attrition when 
individuals die or decline to participate further. Like sample selection, attrition can affect the 
study estimates in longitudinal studies, leading to biased results, particularly because of missing 
data. In Study III, for example, disability was an outcome; we could have underestimated the 
association between exposure and disability because people might have died before 
experiencing disability. However, in sensitivity analyses, using joint regression models, we 
accounted for the competing effect of death, modelling our outcomes (walking speed and B-
ADL score) together with mortality data.   
5.7.2.2 Information (measurement) bias  
This systematic error occurs when the assessment of participants’ characteristics is vitiated by 
factors dependent either on the assessors or the participants themselves. Namely, the way 
specific information is measured, asked for, reported, and noted may cause a misclassification 
of the participants. Misclassification may be differential or nondifferential. In the first case, the 
proportion of misclassification is differentially distributed across different study groups, and 
potentially biases the estimations. Conversely, nondifferential misclassification results are 
randomly distributed across the groups of interest and may dilute the extent of the effect.  
Virtually all the variables considered in our studies may be subject to information bias. Chronic 
disease, for instance, when self-reported, is susceptible to both overreporting and 
underreporting and can be responsible for a differential misclassification of participants. To 
overcome this problem in the present thesis, we maximized the sensitivity of disease detection 
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by gathering information from several sources, including clinical examination, instrumental 
tests, blood tests, medication, and both inpatient and outpatient data. The prevalence of 
multimorbidity we obtained by applying this methodology is among the highest reported in the 
literature. Similarly, the assessment of the outcomes (excluding mortality) and several 
covariates may be biased by the abovementioned factors. However, the use of a rigorous and 
validated methodology, like the one applied in SNAC-K, is expected to minimize such 
possibility.        
5.7.2.3 Confounding  
A problem common to epidemiological studies is to observe an association between two 
measures that should actually be explained by the distribution across groups of a third variable, 
a confounder. Potential confounders are typically risk factors for the outcome, are associated 
with the exposure but are not surrogates of it, and usually precede (temporally) the exposure. 
We handled the problem in the data analyses by either stratifying or adjusting the analyses for 
confounders. Although the analyses in all four papers of this thesis were adjusted for a number 
of factors we deemed to be potential confounders, also considering their variation over time 
(i.e., Study III), we cannot completely rule out the presence of residual confounding.   
5.7.3 Generalizability 
One of the aims of research is to produce generalizable results, namely the possibility of 
applying the findings of a study to other populations, or to all human beings. However, all the 
abovementioned types of bias contribute to affect the generalizability of a given study, and in 
general it is considered impossible to exactly reproduce the characteristics of the whole 
population through a subset of it. For example, as mentioned, the SNAC-K sample population 
resulted in a healthier and wealthier sample, compared with the actual population living in the 
Kungsholmen district of Stockholm, and such differences are likely to be even more 
accentuated if the comparison is made with the rest of the Swedish or European population. 
For these reasons, caution is recommended when the results of our studies are generalized to 
other settings. However, if this is true when attempting to generalize prevalence and incidence 
figures (or other descriptive statistics) from one setting to another, it is less of a problem when 
examining associations for findings with a strong biological plausibility and clear or well-
known underlying biological mechanisms. Knowing the biological bases of the observed 
phenomena helps us to better design a study and to account for specific confounders. In other 
words, what makes generalizability possible in most cases is good biological plausibility and 
knowledge of the underlying mechanisms, not only a representative sample.   
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5.8 CONCLUSIONS 
 
1. We provided a clinically driven list of 60 chronic diseases for the study of 
multimorbidity in older adults. Upon applying the methodology to a population-based 
cohort of individuals aged 60 years or older, 9 in 10 of them were found to be affected 
by two or more diseases. The use of a standardized methodology to assess chronic 
disease and multimorbidity may enhance the comparability across studies, clinical 
settings, and geographical regions.  
 
 
2. Clinical trajectories of older adults with multimorbidity are characterized by great 
dynamism and complexity but can still be tracked over time. The presence  of several 
cardiometabolic risk factors, the evolution and consequences of several diseases, as 
well as death, steer most of the longitudinal transitions among the multimorbidity 
clusters we identified over a period of 12 years. Studying the natural evolution of 
multimorbidity in older individuals may help to better hypothesize underlying 
mechanisms and provide important prognostic information.  
 
 
3. Patterns of multimorbidity combining cardiovascular and neuropsychiatric diseases are 
differentially associated with walking speed decline and disability in older adults. 
Neuropsychiatric disease, alone or combined with cardiovascular disease, exterts the 
strongest detrimental impact on functional decline. Cardiovascular multimorbidity 
shows an association solely with decline in walking speed. Accounting for specific 
combinations of chronic diseases may provide important prognostic information related 
to the speed of physical function decline in older individuals.  
 
4. In older individuals, slow walking speed, a marker of motor impairment, provides 
additional prognostic information in terms of all-cause and cause-specific mortality, 
beyond the number of both cardiovascular and/or neuropsychiatric diseases. The 
adoption of a simple and easy-to-use measure of functional impairment such as walking 
speed may help health-care professionals identify older people affected by specific 
groups of chronic disease with similar needs, health trajectories, and prognoses.       
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6 RELEVANCE AND IMPLICATIONS 
The rapid growth in the number and proportion of older adults demands that societies 
worldwide take action and find sustainable ways to promote and maintain seniors’ health. In 
this regard, the epidemiological and biomedical research fields play a role of utmost 
importance. The first, describing the natural course of specific phenomena, help us recognize 
the common patterns upon which person-centered medicine can be built. The second, revealing 
the underlying mechanisms of such processes, provides the knowledge to implement effective 
preventive and curative strategies. 
With the present thesis, we aimed to contribute mainly to the first issue. First, we provided a 
reliable and rigorous tool for the assessment of chronic disease and multimorbidity in the older 
population. The availability of an alphabet represents the first step toward the development of 
a common language. The lack of a shared methodology has strongly limited the 
comparability—and sometimes validity—of most studies to date in the field of multimorbidity, 
sometimes weakening the concept of multimorbidity itself. Our wish is to have contributed to 
reducing the methodological noise of future studies in this field.  
Second, with this thesis we try to advance toward an alternative way of operationalizing 
multimorbidity, namely through the evaluation of multimorbidity clusters. Counting diseases 
independently from which diseases, and drawing a line between having zero or one and two or 
more diseases would appear to be reductionist and easily questionable approaches. The idea of 
multimorbidity clusters is backed up by strong biological plausibility and confers to the concept 
of multimorbidity the qualitative perspective that has been lacking. In addition, the approach 
in this thesis strives to recognize the expected dynamicity of multimorbidity clusters. Their 
natural evolution over time is described here for the first time through a novel methodology, 
and such dynamism is included in evaluating the impact of specific multimorbidity patterns on 
functional decline. In doing so, we hope to contribute to the identification of specific subgroups 
of older individuals characterized by similar health care needs and trajectories.  
Finally, beyond studying the impact of cardiovascular and neuropsychiatric multimorbidity on 
functional decline, we investigated for the first time the interplay between multimorbidity 
clusters and function. We conclude that the complementary information gained from functional 
and morbidity status can be used to further select the share of the older population in higher 
need of clinical interventions and care.                       
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7 FUTURE DIRECTIONS 
The present thesis contributes to a better description of the occurrence, evolution, and prognosis 
of multimorbidity in older individuals. As a brick is part of a wall, however, it requires further 
support from other pieces of evidence and needs to be extended for a deeper knowledge of the 
phenomenon. First, the goodness of our clinically driven methodology for the assessment of 
multimorbidity requires further confirmation in other populations and settings (specifically, the 
clinical setting). One of our aims was to provide a flexible methodology that was rooted in the 
ICD-10 classification system and could be easily adapted or updated in the future. Second, our 
attempt to describe the longitudinal evolution of multimorbidity clusters is limited by the fact 
that our observations are left-censored at 60 years. In line with the life-course approach 
advocated today in aging research, studies of younger cohorts of individuals would shed further 
light on the phenomenon of multimorbidity. Third, the interplay between multimorbidity and 
functional impairment needs to be better understood. Such interplay may, to a certain extent, 
reflect an overlap between disease and function, rather than a synergistic effect. Longer 
observation periods, starting earlier in individuals’ lives, may help to untangle this aspect.  
Despite knowledge gleaned about the occurrence and prognosis of multimorbidity in older 
individuals in the last two decades, little is known about the biological mechanisms underlying 
the accumulation—and in particular the faster accumulation—of chronic disease. It is a 
common idea that disease accumulation is the signature of the aging process, and that the faster 
accumulation of disease in some individuals reflects their faster aging than other individuals. 
Multimorbidity may represent an optimal model for studying the secrets of the aging process 
in humans.
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